var title_f7_28_7616="Normal physiologic cupping";
var content_f7_28_7616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F71031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F71031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal physiologic cupping",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal physiologic cupping in a large optic disc. Cup:disc ratio is 0.6.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Karl C Golnik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7616=[""].join("\n");
var outline_f7_28_7616=null;
var title_f7_28_7617="Securing endotracheal tube";
var content_f7_28_7617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Securing the endotracheal tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Securing the endotracheal tube. A) The tape is split into a Y and the base is applied to the cheek. B) One strip of tape is then applied to the skin above or below the lips while the other secures the tube. A second piece of tape may be applied from the other side in a similar manner for greater stability. Tincture of benzoin also may be used to increase adhesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: King C, Rappaport LD. Emergent endotracheal intubation. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7617=[""].join("\n");
var outline_f7_28_7617=null;
var title_f7_28_7618="IMRT prostate cancer target vol";
var content_f7_28_7618=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Planning target volume (PTV) for intensity modulated radiation therapy (IMRT) of prostate cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 127px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The two intraprostatic lesions were initially identified on magnetic resonance scanning, then registered onto treatment planning CT images. (A): Coronal image of the PTV contoured in red, with the dominant intraprostatic lesion at left base of the prostate (DIL1) contoured in pink (yellow arrow), and the dominant intraprostatic lesion at right apex of the prostate (DIL2) contoured in orange (yellow arrowhead); (B) Axial image, demonstrating the PTV and the DIL2 with the rectum in purple; (C) Axial image of the PTV and the DIL1 with the bladder in blue (yellow arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Xia P, et al. Int J Radiat Oncol Biol Phys 2001; 51:244. Copyright &copy; 2001 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7618=[""].join("\n");
var outline_f7_28_7618=null;
var title_f7_28_7619="Patient information: Pituitary adenoma (The Basics)";
var content_f7_28_7619=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82820\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39503\">",
"         Pituitary gland",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44608\">",
"          Surgery to remove a pituitary tumor",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/4/36930\">",
"         Patient information: Absent or irregular periods (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/8/40066\">",
"         Patient information: Acromegaly (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/61/6099\">",
"         Patient information: Cushing's syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/26/17826\">",
"         Patient information: Growth hormone treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/9/22674\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/6/25698\">",
"         Patient information: Prolactinoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/12/29891\">",
"         Patient information: Absent or irregular periods (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/27/43443\">",
"         Patient information: Acromegaly (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/19/13619\">",
"         Patient information: Cushing's syndrome (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/0/25603\">",
"         Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/6/3172\">",
"         Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pituitary adenoma (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pituitary-adenoma-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H20131711\">",
"      <span class=\"h1\">",
"       What is a pituitary adenoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pituitary adenoma is an abnormal growth in the pituitary gland. The pituitary gland is located at the base of the brain (",
"      <a class=\"graphic graphic_figure graphicRef72262 \" href=\"UTD.htm?38/36/39503\">",
"       figure 1",
"      </a>",
"      ). The pituitary gland has different cells in it that make different types of hormones. There are different types of pituitary adenomas, depending on which cells are involved.",
"     </p>",
"     <p>",
"      Pituitary adenomas can cause problems in different ways:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        They can make too much of a certain hormone.",
"       </li>",
"       <li>",
"        They can press on nearby tissues in the head, such as the nerves that go from the eye to the brain. This can cause vision problems.",
"       </li>",
"       <li>",
"        They can press on other cells in the pituitary gland and keep those cells from making enough hormone.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20131726\">",
"      <span class=\"h1\">",
"       What are the symptoms of a pituitary adenoma?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms depend on the type of pituitary adenoma you have and how big it is.",
"     </p>",
"     <p>",
"      Some pituitary adenomas, especially small ones, cause no symptoms. People find out they have it after their doctor does an imaging test of their brain for another reason. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      When pituitary adenomas cause symptoms, the symptoms can be from having abnormally high levels of hormones in the body. Depending on the hormone involved, this can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Absent or irregular monthly periods (in women)",
"       </li>",
"       <li>",
"        A low sex drive or trouble getting an erection (in men)",
"       </li>",
"       <li>",
"        A condition called &ldquo;acromegaly&rdquo; &ndash; This is when some parts of the body (especially the hands, feet, and jaw) grow bigger than normal. This usually happens over a long time.",
"       </li>",
"       <li>",
"        A condition called &ldquo;Cushing&rsquo;s syndrome&rdquo; &ndash; This condition can cause medical problems such as weight gain, high blood pressure, thin bones, and weak muscles.",
"       </li>",
"       <li>",
"        A condition called &ldquo;hyperthyroidism&rdquo; &ndash; This can make people feel shaky, nervous, or tired.",
"       </li>",
"       <li>",
"        A condition called &ldquo;gigantism&rdquo; (in children) &ndash; This condition causes children to grow very fast and taller than other children their age. Children with this condition sometimes have large heads.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Symptoms can also happen if the pituitary adenoma grows big or presses on nearby tissues. These symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Vision changes",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20131758\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Tests for a pituitary adenoma include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hormone tests &ndash; Your doctor will do blood and urine tests to measure the levels of different hormones in your body.",
"       </li>",
"       <li>",
"        An imaging test, called an MRI scan, of your brain",
"       </li>",
"       <li>",
"        Vision tests &ndash; Your doctor might order tests to check your vision.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20131773\">",
"      <span class=\"h1\">",
"       How is a pituitary adenoma treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pituitary adenoma that is found by chance and causes no symptoms does not usually need treatment. But the doctor will monitor the growth over time by doing regular follow-up tests.",
"     </p>",
"     <p>",
"      A large pituitary adenoma or a pituitary adenoma that causes symptoms usually needs treatment. Treatment depends on the type of pituitary adenoma you have, how big it is, and your symptoms.",
"     </p>",
"     <p>",
"      The different treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; Many pituitary adenomas are treated with surgery. During surgery, the doctor makes a small cut in the back of the nose and then uses a special tool to take out the growth (",
"        <a class=\"graphic graphic_figure graphicRef75464 \" href=\"UTD.htm?43/36/44608\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Medicines &ndash; Medicines are used instead of surgery for some types of pituitary adenomas. The medicines can shrink the growths and lower the amount of hormones they make. But medicines do not work for all types of pituitary adenomas.",
"       </li>",
"       <li>",
"        Radiation &ndash; Radiation uses high doses of X-rays to destroy or shrink the growth. Doctors usually use radiation after surgery to keep a pituitary adenoma from growing back.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After treatment, your doctor might do regular follow-up tests to monitor your pituitary adenoma and make sure it doesn&rsquo;t grow back. Some people also need long-term hormone treatment to correct the hormone levels in their body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20131811\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, you should talk with your doctor. Your doctor might want to treat your pituitary adenoma before you start trying to get pregnant. Plus, if you take medicines for your pituitary adenoma, your doctor will check that the medicines are safe to take during pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H20131826\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=see_link\">",
"       Patient information: Prolactinoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"       Patient information: Acromegaly (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=see_link\">",
"       Patient information: Cushing's syndrome (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=see_link\">",
"       Patient information: Absent or irregular periods (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=see_link\">",
"       Patient information: Growth hormone treatment (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=see_link\">",
"       Patient information: Cushing's syndrome (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=see_link\">",
"       Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=see_link\">",
"       Patient information: Acromegaly (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"       Patient information: Absent or irregular periods (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/28/7619?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82820 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-5866CBA7F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7619=[""].join("\n");
var outline_f7_28_7619=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131711\">",
"      What is a pituitary adenoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131726\">",
"      What are the symptoms of a pituitary adenoma?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131758\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131773\">",
"      How is a pituitary adenoma treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131811\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20131826\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39503\">",
"      Pituitary gland",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/36/44608\">",
"       Surgery to remove a pituitary tumor",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=related_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/4/36930?source=related_link\">",
"      Patient information: Absent or irregular periods (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/27/43443?source=related_link\">",
"      Patient information: Acromegaly (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=related_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/19/13619?source=related_link\">",
"      Patient information: Cushing's syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/61/6099?source=related_link\">",
"      Patient information: Cushing's syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/26/17826?source=related_link\">",
"      Patient information: Growth hormone treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/0/25603?source=related_link\">",
"      Patient information: High prolactin levels and prolactinomas (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25698?source=related_link\">",
"      Patient information: Prolactinoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7620="Permanent sterilization procedures for women";
var content_f7_28_7620=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Permanent sterilization procedures for women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/28/7620/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7620/contributors\" id=\"au5417\">",
"       Thomas G Stovall, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7620/contributors\" id=\"au5145\">",
"       William J Mann, Jr, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/28/7620/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7620/contributors\" id=\"se197\">",
"       Tommaso Falcone, MD, FRCSC, FACOG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?7/28/7620/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7620/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?7/28/7620?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Surgical sterilization is a safe, highly effective, permanent, and convenient form of contraception. The most common surgical sterilization procedure for women is called a tubal ligation or having the \"tubes tied.\" The fallopian tubes are attached to the uterus and adjacent to the ovaries (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). The fallopian tubes are the site where the egg becomes fertilized by the male's sperm prior to traveling to the uterus. In tubal sterilization, the fallopian tubes are separated or sealed shut, thus preventing the egg and sperm from meeting.",
"    </p>",
"    <p>",
"     Sterilization may be performed in one of several ways, depending upon where the procedure is done (office versus operating room) and when it is done (after childbirth or at another time).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Laparoscopic sterilization is done in the operating room any time other than after childbirth. It requires general or regional (eg, spinal) anesthesia. (See",
"       <a class=\"local\" href=\"#H8\">",
"        'Laparoscopic sterilization'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Minilaparotomy is performed in an operating room, using general or regional anesthesia, often one to two days after a woman gives birth. (See",
"       <a class=\"local\" href=\"#H9\">",
"        'Minilaparotomy'",
"       </a>",
"       below.)",
"      </li>",
"      <li>",
"       Hysteroscopic sterilization may be done in the office or operating room, requires only local anesthesia, and is done at a time other than after childbirth. (See",
"       <a class=\"local\" href=\"#H10\">",
"        'Hysteroscopic sterilization'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other methods of birth control are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      \"Patient information: Birth control; which method is right for me? (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DECIDING TO HAVE A TUBAL LIGATION",
"     </span>",
"    </p>",
"    <p>",
"     Sterilization is a major decision; it means that a woman and her partner do not want children at any time in the future. A woman's decision to undergo sterilization must be voluntary and not forced by her family, partner, or healthcare provider.",
"    </p>",
"    <p>",
"     In the United States, a woman's husband or partner is not required to give consent for the procedure, although both partners should have an understanding of the procedure as well as tubal sterilization's benefits, alternatives, and potential risks. The woman and her partner should review the risks and benefits of all methods of contraception, including male sterilization (vasectomy). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/2/29730?source=see_link\">",
"      \"Patient information: Vasectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The physician should provide an explanation of the details of the procedure, including the options for anesthesia (general, spinal, local), and the possibility of pregnancy following the procedure (see",
"     <a class=\"local\" href=\"#H11\">",
"      'Permanent sterilization outcomes'",
"     </a>",
"     below), including the chance of ectopic pregnancy (when a pregnancy begins to grow outside the uterus, usually in the fallopian tubes). A woman may change her mind at anytime before the procedure.",
"    </p>",
"    <p>",
"     Tubal sterilization should be considered permanent; reversing the procedure involves major surgery, is not always successful, and is rarely covered by insurance plans.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Alternatives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alternatives to permanent female sterilization include permanent male sterilization (vasectomy) and reversible types of contraception (birth control",
"     <span class=\"nowrap\">",
"      pills/patch/vaginal",
"     </span>",
"     ring, condoms, diaphragm, cervical cap, intrauterine device, or injection).",
"    </p>",
"    <p>",
"     These methods are discussed in detail in separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/2/29730?source=see_link\">",
"      \"Patient information: Vasectomy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Regret after sterilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Between 3 and 25 percent of women regret their decision to undergo sterilization. However, only about 1 to 2 percent of women undergo a reversal of the procedure [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/1-3\">",
"      1-3",
"     </a>",
"     ]. The most common factor associated with regret is a change in marital status. Other factors include marital problems at the time of procedure, stress due to recent pregnancy complications, and young age (less than age 30) at the time of sterilization.",
"    </p>",
"    <p>",
"     For these reasons, women who are younger than 30, have recently given birth and had significant complications (eg, premature birth, death of an infant), or who are having difficulty with their marriage or relationship should initially consider other birth control options. A healthcare provider may recommend that sterilization be delayed until the woman is sure of her decision, is aware of the risks and benefits, and is aware of the alternatives to permanent sterilization.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Timing of sterilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sterilization can be performed at any time during a woman's menstrual cycle, although having the procedure just after the menstrual period reduces the risk that the woman will be pregnant at the time of the surgery.",
"    </p>",
"    <p>",
"     Sterilization can also be performed after childbirth (postpartum), after an abortion, or in conjunction with another surgical procedure (eg, gallbladder removal). Ideally, postpartum procedures are performed immediately after childbirth or within 24 hours, although the procedure may be done up to seven days later. Delaying the procedure for more than 7 days increases the difficulty of the procedure and the risk of infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Preventing pregnancy before and after sterilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some form of birth control (condom, diaphragm, birth control pill, etc) should be used before sterilization to decrease the risk of pregnancy. A woman can become pregnant if fertilization occurs just prior to the procedure. Performing the procedure immediately postpartum or during a woman's menstrual period reduces the chance of becoming pregnant at the time of the procedure. However, it is possible to have a sensitive urine or blood pregnancy test on the day of the procedure to reduce the chances of having the procedure while pregnant.",
"    </p>",
"    <p>",
"     Although birth control is not necessary after the procedure, condoms are recommended to reduce the risk of becoming infected with a sexually transmitted disease (eg, chlamydia, HIV), especially if the woman has multiple sex partners or has a partner with other partners. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      \"Patient information: Barrier methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PERMANENT STERILIZATION PROCEDURES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Laparoscopic sterilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Laparoscopic sterilization is a surgical procedure that is done in an operating room at a time other than after childbirth. General or regional (eg, spinal) anesthesia is usually recommended. During the procedure, a small incision is made near the belly button and in the lower abdomen and a telescope-like device (a laparoscope) is used to view the fallopian tubes. The physician uses rings or clips to close the fallopian tubes; alternately, the physician seals the tubes shut with heat.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Minilaparotomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A minilaparotomy is a surgical procedure done one to two days after childbirth. It is done in an operating room using general, regional, or local anesthesia. The physician makes a small incision (one to three inches) in the abdomen, then removes a section of the fallopian tubes on each side. In the postpartum period, the procedure does not lengthen the hospital stay.",
"    </p>",
"    <p>",
"     One advantage of minilaparotomy is that a tissue specimen is removed to ensure that the fallopian tubes have been completely cut. Disadvantages of minilaparotomy include a greater need for pain medication, a slightly longer recovery time, and a larger surgical incision than with a laparoscopic procedure [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Hysteroscopic sterilization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hysteroscopic sterilization is a procedure that may be done in the office or operating room using local anesthesia. The Essure permanent birth control procedure uses a tiny coil mechanism, which is inserted through the cervix and uterus into the fallopian tubes (",
"     <a class=\"graphic graphic_picture graphicRef55795 \" href=\"UTD.htm?23/15/23792\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     After the coil or insert is placed, scar tissue develops, causing the tubes to become sealed shut. The woman must use another form of birth control for three months after the coil is placed. At this time, an imaging test called hysterosalpingogram is performed to confirm that the tubes are blocked. If the tubes are not completely blocked, the procedure may be repeated.",
"    </p>",
"    <p>",
"     Hysteroscopic sterilization is best done seven to ten days after the start of a woman's menstrual period. In some cases, the provider will recommended an injectable birth control treatment",
"     <span class=\"nowrap\">",
"      (medroxyprogesterone acetate/Depo",
"     </span>",
"     Provera) two to three weeks before the procedure to make it easier to place the coils (and eliminate the risk of pregnancy",
"     <span class=\"nowrap\">",
"      before/after",
"     </span>",
"     the procedure).",
"    </p>",
"    <p>",
"     The advantages of hysteroscopic sterilization are that no sedation or general anesthesia are required (eg, the woman is not sleepy and may drive herself home), and there are no incisions. Compared to other forms of surgical sterilization, hysteroscopic sterilization costs less, allows the woman to spend less time in the hospital, is well tolerated, and causes less severe post-operative pain.",
"    </p>",
"    <p>",
"     The disadvantages of hysteroscopic sterilization include the need for an alternate form of birth control for three months after the coil is placed and the potential need to repeat the procedure. In one study, approximately 15 percent of women did not have complete blockage of one or both tubes after three months [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PERMANENT STERILIZATION OUTCOMES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Complications of laparoscopic and minilaparotomy procedures occur in approximately 1 of every 1000 procedures. The most common complications include infection, bowel or bladder injury, internal bleeding, and problems related to anesthesia.",
"    </p>",
"    <p>",
"     The complication rate with hysteroscopic sterilization is approximately 0.02 per 1000 procedures. The most common complication is perforation of the uterus (when an instrument creates a small tear through the uterine wall). This does not usually require treatment and does not have any long-term consequences.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Menstrual periods",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no evidence that bleeding or uterine cramping increases after sterilization. In fact, women who undergo sterilization are more likely to have fewer days of bleeding during menstruation, a lower amount of blood loss, and less menstrual pain. However, sterilized women have described more cycle irregularity than women who were not sterilized.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Sexual desire",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sterilization does not affect sexual desire or performance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is uncommon for sterilization to fail, allowing a woman to become pregnant. In one study of women who had laparoscopic or minilaparotomy sterilization and were followed for 8 to 14 years, approximately 1 percent of women became pregnant [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/5\">",
"      5",
"     </a>",
"     ] (",
"     <a class=\"graphic graphic_table graphicRef70218 \" href=\"UTD.htm?12/56/13197\">",
"      table 1",
"     </a>",
"     ). The risk of pregnancy was highest among women who underwent sterilization at a young age (under age 30) and among women who had clips placed on the tubes.",
"    </p>",
"    <p>",
"     The failure rate for hysteroscopic sterilization is also quite low, estimated to be less than 1 percent [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     When pregnancy occurs after a sterilization procedure, it is more likely to be an ectopic pregnancy. For this reason, any woman who has had undergone sterilization and then misses or is late for a menstrual period should consult her healthcare provider for advice about the need for a pregnancy test. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"      \"Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      AFTER PERMANENT STERILIZATION SURGERY",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Laparoscopy and minilaparotomy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A few hours after laparoscopic or minilaparotomy sterilization, most women are able to go home. Someone should be available to drive and help as needed. There will be some discomfort at the incision site and menstrual-type cramping; this can be treated with pain medication such acetaminophen (Tylenol) or ibuprofen (Advil, Motrin). Some women will have a sore throat (from a tube placed to help with breathing during general anesthesia), neck or shoulder pain, vaginal discharge, or light bleeding.",
"    </p>",
"    <p>",
"     Most women are able to return to a normal routine within a couple of days. The woman is usually instructed not place anything in the vagina (eg, tampons, douches) and to avoid sexual intercourse sex for approximately two weeks. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"      \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Hysteroscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Following hysteroscopic sterilization, most women are able to drive themselves home or back to",
"     <span class=\"nowrap\">",
"      work/school.",
"     </span>",
"     If a sedative was used, the woman should have someone else drive her home. Most women experience mild cramping, which can be treated with an over-the-counter pain medication such as acetaminophen (Tylenol) or ibuprofen (Advil, Motrin). A small amount of vaginal bleeding or discharge may occur for a few days after the procedure; no treatment is required. Most women are able to return to normal activities the same day.",
"    </p>",
"    <p>",
"     The woman should be sure to use an additional form of birth control (eg, pills, condoms, diaphragm) until a test is done, usually three months later, to confirm that both tubes are completely blocked.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H191\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696433\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/56/14211?source=see_link\">",
"      Patient information: Choosing birth control (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/25/36242?source=see_link\">",
"      Patient information: Vasectomy (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15696441\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/2/22563?source=see_link\">",
"      Patient information: Barrier methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/60/9157?source=see_link\">",
"      Patient information: Birth control; which method is right for me? (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/2/29730?source=see_link\">",
"      Patient information: Vasectomy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/43/38578?source=see_link\">",
"      Patient information: Ectopic (tubal) pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42201?source=see_link\">",
"      Contraception: Overview of issues specific to adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/5/31833?source=see_link\">",
"      Emergency contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5334?source=see_link\">",
"      Female condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/58/37800?source=see_link\">",
"      Fertility awareness-based methods of pregnancy prevention",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/47/3832?source=see_link\">",
"      Hormonal contraception for suppression of menstruation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/38/20070?source=see_link\">",
"      Barrier contraception: Diaphragm",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30696?source=see_link\">",
"      Male condoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39306?source=see_link\">",
"      Overview of contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/5/18522?source=see_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39893?source=see_link\">",
"      Overview of vasectomy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/52/9031?source=see_link\">",
"      Progestin-only pills (minipills) for contraception",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"      Surgical sterilization of women",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Planned Parenthood",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.plannedparenthood.org/\">",
"      www.plannedparenthood.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Society of Obstetricians and Gynaecologists of Canada (SOGC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.sogc.org/health/health_e.asp\">",
"      www.sogc.org/health/health_e.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Managing Contraception",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.managingcontraception.com/index.php?go=choices\">",
"      www.managingcontraception.com/index.php?go=choices",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?7/28/7620/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?7/28/7620?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/1\">",
"      Grubb GS, Peterson HB, Layde PM, Rubin GL. Regret after decision to have a tubal sterilization. Fertil Steril 1985; 44:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/2\">",
"      Allyn DP, Leton DA, Westcott NA, Hale RW. Presterilization counseling and women's regret about having been sterilized. J Reprod Med 1986; 31:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/3\">",
"      Wilcox LS, Chu SY, Eaker ED, et al. Risk factors for regret after tubal sterilization: 5 years of follow-up in a prospective study. Fertil Steril 1991; 55:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/4\">",
"      Cooper JM, Carignan CS, Cher D, et al. Microinsert nonincisional hysteroscopic sterilization. Obstet Gynecol 2003; 102:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/5\">",
"      Peterson HB, Xia Z, Hughes JM, et al. The risk of pregnancy after tubal sterilization: findings from the U.S. Collaborative Review of Sterilization. Am J Obstet Gynecol 1996; 174:1161.",
"     </a>",
"    </li>",
"    <li>",
"     Data from Conceptus Incorporated, San Carlos, CA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7620/abstract/7\">",
"      Levy B, Levie MD, Childers ME. A summary of reported pregnancies after hysteroscopic sterilization. J Minim Invasive Gynecol 2007; 14:271.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f7_28_7620=[""].join("\n");
var outline_f7_28_7620=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DECIDING TO HAVE A TUBAL LIGATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PERMANENT STERILIZATION PROCEDURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PERMANENT STERILIZATION OUTCOMES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           AFTER PERMANENT STERILIZATION SURGERY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/15/23792\" title=\"picture 1\">",
"           Hyst microinsert PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13197\" title=\"table 1\">",
"           Pregnancy rate during first year of contraception",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7621="Weight-resistance exercises in patients with osteoarthritis";
var content_f7_28_7621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Weight-resistance exercises in patients with osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7621/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/28/7621/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review describes the basic weight-resistance exercises that can be used as part of the therapeutic regimen in patients with osteoarthritis (OA). An overview of the approach to weight-resistance training in patients with OA is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link\">",
"     \"Weight-resistance training in patients with osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exercises are listed by the type of exercise and target muscle groups, and risks and recommendations for the patient with osteoarthritis are provided. Overall ratings consider both effectiveness and safety issues with a score of one being the worst and five being the best.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BENCH PRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups used are the pectoralis major (",
"    <a class=\"graphic graphic_figure graphicRef57438 \" href=\"UTD.htm?5/9/5279\">",
"     figure 1",
"    </a>",
"    ). These are the most frequently used muscles of the upper body; they are commonly involved in activities that require reaching forward.",
"   </p>",
"   <p>",
"    Risk factors: excessive loads can lead to shoulder injury (rotator cuff tear).",
"   </p>",
"   <p>",
"    Overall rating: 3",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strengthen rotator cuff by doing internal and external rotation exercises before attempting chest exercises. Use other bench press machines such as an isolateral seated bench press machine. Machines use a guided motion, which reduces chances of injury. The seated position is easier for patients with lower extremity OA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERHEAD MILITARY PRESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;These exercises work the lateral and anterior deltoids, which are used in activities involving raising the arms over the head.",
"   </p>",
"   <p>",
"    Risk factors: shoulder injury (impingement)",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoid if impingement is present. Instead, perform lateral raises with cable pulleys or free weights, which limit range of motion and reduce impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     UPRIGHT ROWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the anterior and lateral deltoids, used in activities in which the arms are raised over the head.",
"   </p>",
"   <p>",
"    Risk factors: impingement and excessive strain on wrists due to narrow grip and upward pulling motion",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoid if impingement is present. Instead, perform lateral raises with cable pulleys or free weights, which limit range of motion and reduce impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LATERAL RAISES WITH CABLE PULLEYS OR FREE WEIGHTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle group involved is the anterior and lateral deltoids, used in activities in which the arms are raised over the head.",
"   </p>",
"   <p>",
"    Risk factors: may exacerbate wrist or hand symptoms with underlying arthritis if heavy weights are used",
"   </p>",
"   <p>",
"    Overall rating: 4",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are safer than overhead military presses or upright rows because lateral raises limit range of motion and reduce impingement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TRICEP PRESS-DOWNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the triceps, latissimus dorsi, and serratus anterior, which are used to push off of arm rests while getting out of a chair.",
"   </p>",
"   <p>",
"    Risk factors: wrist pain due to hyperextension and elbow pain due to hyperflexion",
"   </p>",
"   <p>",
"    Overall rating: 4",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use a seated triceps extension machine. Keep wrist neutral through entire range of motion. Do not allow less than 90 degrees of elbow flexion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRICEPS PUSH-UPS (DIPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the triceps, latissimus dorsi, and serratus anterior, which are used to push off of arm rests while getting out of a chair.",
"   </p>",
"   <p>",
"    Risk factors: excessive strain on acromioclavicular joint due to lowering the body too far. Most people cannot support their own weight with their arms.",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Try using triceps press-downs or a seated triceps extension machine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BICEP CURLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the biceps, used during supination of the wrists and flexion of the elbow joint (",
"    <a class=\"graphic graphic_figure graphicRef74873 \" href=\"UTD.htm?14/34/14894\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Risk factors: wrist pain due to excessive wrist supination",
"   </p>",
"   <p>",
"    Overall rating: 5",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoid using a straight bar; instead, use dumbbells or an EZ curl bar (a bar shaped like a &ldquo;W&rdquo; that requires less supination than a straight bar). These exercises should be performed while sitting to avoid swinging of the upper body, which causes lower back involvement. Avoid using a preacher-curl bench; positioning of elbows can lead to hyperextension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     BEHIND THE NECK LATERAL PULL DOWNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the latissimus dorsi, teres major and minor, and biceps. This exercise provides inadequate improvement of upper back strength and posture. The effectiveness of back exercises is dependent upon the ability of the participant to retract shoulder blades.",
"   </p>",
"   <p>",
"    Risk factors: poor technique leading to hunched posture can lead to poor alignment of cervical spine, and excessive stretching at the top of this exercise can cause rotator cuff tears.",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any exercise done behind the neck should be",
"    <strong>",
"     avoided",
"    </strong>",
"    . Recommend doing this exercise by pulling bar from the front of the chest. Straps are recommended for people with poor grip strength.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SEATED ROWS (CLOSE GRIP BAR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the lower latissimus dorsi, center traps, rear deltoids, and spinal erectors; all are activated during retraction of the shoulders.",
"   </p>",
"   <p>",
"    Risk factors: phis and all other rowing exercises produce marked lower back involvement and should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in patients with low back pain.",
"   </p>",
"   <p>",
"    Overall rating: 4",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor initiation and technique can turn this exercise into a biceps exercise rather than a back exercise. Straps are recommended for those with poor grip strength. Try using a seated row machine to reduce lower back involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SQUATS (FREE WEIGHTS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the quadriceps femoris. The three main muscles of the quadriceps femoris group are the vastus medialis, lateralis, and rectus femoris. These muscles can be activated when rising from a seated position.",
"   </p>",
"   <p>",
"    Risk factors: resting weights on the shoulders may not be tolerated by patients with arthritis, and improper technique and excessive loads can lead to disc herniation and can also cause knee injuries.",
"   </p>",
"   <p>",
"    Overall rating: 5",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squats are excellent exercises for improving overall functional strength, as well as coordination and balance of the lower extremities if performed correctly. They should be done under close supervision to ensure that the participant is maintaining proper alignment of the spine and is not flexing the knees more than 90 degrees. A spotter (someone who ensures that the weight lifter does not lose control of the weights) should be present. If there is no spotter, try using a Smith machine for squats or a leg press, which provides guided motion and reduces the likelihood of improper technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LUNGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the quadriceps, adductor group, and gluteus maximus (",
"    <a class=\"graphic graphic_figure graphicRef65588 \" href=\"UTD.htm?21/59/22463\">",
"     figure 3",
"    </a>",
"    ). The quadriceps and gluteus maximus are activated during walking, running, sitting, and standing, while the adductor group is responsible for adduction of the hip. Functional uses of the adductors are walking, running, and crossing the legs.",
"   </p>",
"   <p>",
"    Risk factors: lunges are a very advanced movement and require a greater amount of balance and coordination; if performed incorrectly, lunges can place excessive strain on the knee and lower back.",
"   </p>",
"   <p>",
"    Overall rating: 4",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lunges should be performed with strict form and under supervision. The front of the knee should not be allowed to extend beyond the tip of the foot, and the back must be kept straight through the entire motion. The exercise should be tried initially without any weight to ensure proper form. If the movement is too difficult, the Smith-machine squat should be tried; Smith-machine squats provide guided motion, assist in technique, and reduce the amount of balance and coordination required to execute this exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PARTIAL (ROMANIAN-STYLE) DEAD-LIFTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the hamstrings. The hamstrings, comprised of the biceps femoris, semitendinosus, and semimembranosus, are responsible for flexion of the knee joint.",
"   </p>",
"   <p>",
"    Risk factors: this is a highly advanced exercise. If done incorrectly, it can put extreme strain on the lower back. If done correctly, however, it can be very effective in improving the strength and size of the hamstrings. Partial dead-lifts differ from straight-legged dead-lifts in that partial dead-lifts require less forward flexion at the hips. Straight-legged exercises are performed with locked knees while partial dead-lifts are not.",
"   </p>",
"   <p>",
"    Overall rating: 2",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The integrity of the spine should be maintained during the entire motion of this exercise. Straps are recommended since grip strength is essential for this exercise. Partial dead-lifts should be done with extremely low weights. They should be",
"    <strong>",
"     avoided",
"    </strong>",
"    by people with low back pain who should substitute cable pulleys of leg extensions, although both are open-chain exercises, which have some risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=see_link&amp;anchor=H4#H4\">",
"     \"Weight-resistance training in patients with osteoarthritis\", section on 'Open- versus closed-chain exercises'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     LEG PRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the quadriceps, which are activated when rising from a seated position.",
"   </p>",
"   <p>",
"    Risk factors: leg presses are highly risky if excessive loads are placed on the machine and if the knees are flexed more than 90 degrees.",
"   </p>",
"   <p>",
"    Overall rating: 4",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;When placing the feet on the platform of the leg press, make sure they are comfortably placed at about shoulder width. Initiate the exercise slowly and do not bend above 90 degrees of flexion. Do not overload the machine with weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     LEG EXTENSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the quadriceps, which are activated during extension of the knee (",
"    <a class=\"graphic graphic_figure graphicRef78243 \" href=\"UTD.htm?5/26/5551\">",
"     figure 4",
"    </a>",
"    ). Functional uses of these muscles are walking, running, and getting in and out of a chair or car.",
"   </p>",
"   <p>",
"    Risk factors: leg extensions are an open-chain exercise, which place an excessive amount of shear forces on the internal structures of the knee.",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substitute leg presses, Smith-machine squats, or lunges. These exercises are classified as closed-chain exercises and, if done properly, do not place excessive strain on the knee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     LEG CURLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the biceps femoris, semitendinosus, and semimembranosus. These muscles are activated during flexion of the knee joint. Functional use of these muscles occurs during walking, running, and getting in and out of a chair or car.",
"   </p>",
"   <p>",
"    Risk factors: leg curls are an open-chain exercise that can put strain on the lower back depending upon the design of the particular machine and upon the individual&rsquo;s technique. Shear forces are also applied to the knee during this exercise.",
"   </p>",
"   <p>",
"    Overall rating: 1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substitute partial dead-lifts instead of leg curls. Perform only in patients without lower back problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CALF RAISES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the gastrocnemius and soleus. The gastrocnemius muscles are activated during plantar flexion of the ankle; the soleus is also activated during plantar flexion and assists in knee flexion.",
"   </p>",
"   <p>",
"    Risk factors: most machines can place the ankle joint in hyperflexion and can also place excessive strain on the Achilles tendon.",
"   </p>",
"   <p>",
"    Overall rating: 3",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calf raises can be beneficial in rehabilitation of ankle injuries as long as low weights are used and as long as the ankle joint is not placed in hyperflexion. Most body builders build these muscles for aesthetic purposes, but the average person or a person with arthritis can achieve functional strength in these areas either from walking on a treadmill or from riding a bicycle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     ABDOMINAL CRUNCHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscle groups involved are the recti abdominus. The abdominal muscles are responsible for forward flexion of the torso; these muscles are recruited during any form of activity (",
"    <a class=\"graphic graphic_figure graphicRef80909 \" href=\"UTD.htm?9/10/9391\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Risk factors: doing abdominal crunches can put strain on the cervical spine. During the initiation of exercise, some people might have a tendency to pull on the neck during the upward motion of the exercise. If the range of motion goes beyond 30 degrees, the psoas muscles are activated and can place excessive strain on the lower back; going beyond 30 degrees can also activate the hip flexors.",
"   </p>",
"   <p>",
"    Overall rating: 5",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal crunches are helpful in providing support for the lower back. There are several machines that support the head and can be helpful in performing this exercise, but not all machines are made for all body types. The knees should be bent, and the exercise should be initiated by raising the shoulders off the ground 30 degrees and by pointing the chin towards the ceiling. The head should be supported with both hands, and the head or neck should not be pulled forward to assist in raising the upper body off the ground.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H251383871\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weight-resistance exercises can be used as a component of the therapeutic exercise regimen for osteoarthritis. These exercises can be rated based upon their effectiveness and safety. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercises with a relatively high level of effectiveness and safety include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Lateral raises with cable pulleys or free weights &mdash; for the muscles used in activities in which the arms are raised over the head (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Lateral raises with cable pulleys or free weights'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Triceps press-downs &mdash; for the muscles used to push off of arm rests when getting out of a chair (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Tricep press-downs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Bicep curls &mdash; for the muscles used during supination of the wrists and flexion of the elbow (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Bicep curls'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Seated rows (close grip bar) &mdash; for the muscles activated during retraction of the shoulders (exercise to be avoided in patients with low back pain) (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Seated rows (close grip bar)'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Squats (free weights) &mdash; for the muscles in the leg activated when rising from a seated position (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Squats (free weights)'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lunges &mdash; for the muscles activated during walking, running, sitting, and standing (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Lunges'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Leg press &mdash; for the muscles in the legs activated when rising from a seated position (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Leg press'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Abdominal crunches &mdash; for the muscles responsible for forward flexion of the torso (see",
"      <a class=\"local\" href=\"#H34\">",
"       'Abdominal crunches'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercises with an intermediate level of effectiveness and safety include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bench press &mdash; for the muscles involved in activities that require reaching forward (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Bench press'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Calf raises &mdash; for the muscles involved in plantar flexion of the ankle (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Calf raises'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercises with a relatively low level of effectiveness and safety include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Overhead military presses (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Overhead military presses'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Upright rows (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Upright rows'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Triceps push-ups (dips) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Triceps push-ups (dips)'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Behind the neck lateral pull downs (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Behind the neck lateral pull downs'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Partial (Romanian-style) dead-lifts (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Partial (Romanian-style) dead-lifts'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Leg extensions (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Leg extensions'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Leg curls (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Leg curls'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5505 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7621=[""].join("\n");
var outline_f7_28_7621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H251383871\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BENCH PRESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERHEAD MILITARY PRESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      UPRIGHT ROWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LATERAL RAISES WITH CABLE PULLEYS OR FREE WEIGHTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TRICEP PRESS-DOWNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRICEPS PUSH-UPS (DIPS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BICEP CURLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      BEHIND THE NECK LATERAL PULL DOWNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SEATED ROWS (CLOSE GRIP BAR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SQUATS (FREE WEIGHTS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LUNGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PARTIAL (ROMANIAN-STYLE) DEAD-LIFTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      LEG PRESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      LEG EXTENSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      LEG CURLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CALF RAISES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      ABDOMINAL CRUNCHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H251383871\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5505\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5505|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/9/5279\" title=\"figure 1\">",
"      Bench press",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/34/14894\" title=\"figure 2\">",
"      Biceps curls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/59/22463\" title=\"figure 3\">",
"      Lunge exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/26/5551\" title=\"figure 4\">",
"      Knee extension exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/10/9391\" title=\"figure 5\">",
"      Abdominal crunches exercise",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5427?source=related_link\">",
"      Weight-resistance training in patients with osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7622="Epidemiology of malignant mesothelioma";
var content_f7_28_7622=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of malignant mesothelioma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Daniel H Sterman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Leslie A Litzky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Larry R Kaiser, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Steven M Albelda, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Arthur T Skarin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Andrew Nicholson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7622/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/28/7622/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesothelioma is an insidious neoplasm arising from the mesothelial surfaces of the pleural and peritoneal cavities, the tunica vaginalis, or the pericardium. Eighty percent of all cases are pleural in origin. The predominant cause of malignant mesothelioma is inhalational exposure to asbestos, with approximately 70 percent of cases of pleural mesothelioma being associated with documented asbestos exposure.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology of mesothelioma. The pathology, clinical presentation, evaluation, and staging, and treatment of malignant mesothelioma will be discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=see_link\">",
"     \"Pathology of malignant pleural mesothelioma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=see_link\">",
"     \"Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The annual incidence of mesothelioma in the United States is estimated to be approximately 3300 cases per year [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence of mesothelioma in the United States appears to have peaked around the year 2000 and is now declining, secondary to control of exposure to asbestos [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence is increasing in many other places in the world, particularly in Great Britain, where a peak of up to 2450 deaths per year is expected around the year 2015 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/3\">",
"     3",
"    </a>",
"    ]. After that time, mesothelioma rates are expected to drop in England and other developed countries because of reduced asbestos exposure in the workplace and the general environment. In contrast, mesothelioma incidence rates are predicted to increase dramatically in resource limited settings secondary to poor regulation of asbestos mining and the proliferation of industrial and household utilization of asbestos [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asbestos exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asbestos is the commercial name for a group of hydrated magnesium silicate fibrous minerals. There are two major types: serpentine and amphibole. Ninety percent of the asbestos currently used in the United States is Canadian chrysotile, a serpentine fiber that is reportedly less carcinogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asbestos is valued in industry for its resistance to heat and combustion. It is still used in cement, ceiling and pool tiles, automobile brake linings, and in shipbuilding.",
"   </p>",
"   <p>",
"    As many as eight million living persons in the United States have been occupationally exposed to asbestos over the past 50 years. With the acknowledgment that asbestos exposure may endanger the health of American workers, the Occupational Safety and Health Administration (OSHA) established 5 fibers per cubic milliliter of air as the standard acceptable exposure in 1970. This level has since been reduced to 0.2 fibers per cubic milliliter of air, but this applies only to fibers longer than 5 micrometers. Workers exposed to higher concentrations of regulated fibers are mandated to use protective clothing, respirators, and showers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asbestos workers are at significant risk for the development of both non-malignant and malignant pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=see_link\">",
"     \"Asbestosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 8 percent of asbestos workers will die of respiratory failure secondary to asbestosis.",
"     </li>",
"     <li>",
"      The average asbestos worker has a 50 percent chance of dying from a malignancy, compared to around 18 percent for the average American. The vast majority of cancers in asbestos workers involve the lung, either primary lung carcinoma or mesothelioma.",
"     </li>",
"     <li>",
"      The lifetime risk of developing mesothelioma among asbestos workers is thought to be as high as 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/6\">",
"       6",
"      </a>",
"      ]. There is a latency period of approximately 30 to 40 years from the time of asbestos exposure to the development of mesothelioma.",
"     </li>",
"     <li>",
"      There appears to be a dose-response relationship between asbestos exposure and mesothelioma. This was illustrated in cohort study of 4659 people who resided in an Australian city that produced crocidolite asbestos but who did not directly participate in its mining or milling; the incidence of mesothelioma increased significantly with greater environmental exposure, based upon the neighborhood and duration of residence [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/7\">",
"       7",
"      </a>",
"      ]. In a cohort of textile workers with heavy exposure to asbestos, the risk of pleural mesothelioma was increased and was proportional to the latency period [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asbestos exposure acts synergistically with cigarette smoking to increase the risk of developing lung cancer 60 times over that of a similarly matched non-smoking, non-asbestos-exposed cohort. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=see_link\">",
"       \"Cigarette smoking and other risk factors for lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Asbestos workers are thought to have an increased risk of non-mesothelioma gastrointestinal malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/4,5,9,10\">",
"       4,5,9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Environmental, nonoccupational exposure to asbestos also can contribute to an increased risk of mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. In certain rural areas in Greece, Turkey, and Bulgaria, soil contains remarkably high levels of tremolite asbestos fibers, and many cases of mesothelioma in these regions appear to be secondary to long-term nonoccupational asbestos exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. A role for nonoccupational exposure to asbestos was also supported by a study from California in which an increased incidence of mesothelioma was associated with proximity to naturally occurring asbestos deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asbestos is responsible for a substantial number of cases of peritoneal mesothelioma, although the relationship may be less strong than for pleural mesotheliomas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation to supradiaphragmatic fields may be a risk factor for the subsequent development of mesothelioma, with a long latent period between the initial treatment and the diagnosis of the second malignancy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 77,876 non-Hodgkin lymphoma patients from the Surveillance, Epidemiology and End Results (SEER) database found an increased risk of mesothelioma that was limited to patients who had been treated with radiation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/18\">",
"       18",
"      </a>",
"      ]. The increased risk was highest in those who were less than 25 years of age when they were treated with radiation.",
"     </li>",
"     <li>",
"      An analysis of 21,881 cases of Hodgkin lymphoma and 101,000 patients with non-Hodgkin lymphoma from the SEER database extended and confirmed these earlier observations [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/19\">",
"       19",
"      </a>",
"      ]. Although the number of cases of mesothelioma identified was small, the risk was significantly increased and was limited to those who had received radiation.",
"     </li>",
"     <li>",
"      A population-based series of over 40,000 men treated for testicular cancer between 1943 and 2001 and followed long-term found ten excess cases of pleural mesothelioma (relative risk 4) for men treated with radiation therapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The data for patients with breast cancer are conflicting. An analysis of 22,140 patients treated in 11 National Surgical Adjuvant Breast Project (NSABP) trials identified three cases of mesothelioma, all occurring in women who had received radiation therapy to the ipsilateral thorax [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/21\">",
"       21",
"      </a>",
"      ]. In contrast, a SEER database cohort of over 250,000 could not identify a link between radiation therapy and subsequent development of pleural mesothelioma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although prophylactic mediastinal irradiation is no longer used in testicular germ cell tumors and its use has been sharply curtailed in patients with Hodgkin lymphoma and non-Hodgkin lymphoma, there are a substantial number of cancer survivors who remain at risk for the late development of mesothelioma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Carbon nanotubes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon nanotubes share similar dimensions and chemical properties with asbestos [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/23\">",
"     23",
"    </a>",
"    ]. Studies in animal models have shown that these particles can induce mesothelioma-like changes in susceptible strains of mice following intraperitoneal administration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Carbon nanotubes are being used in an increasing array of applications in the workplace. Epidemiologic vigilance will be required to ensure that these are not a new etiologic source of malignant mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral oncogenes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simian virus-40 (SV-40) is a polyoma virus with oncogenic potential in humans. Its actions are thought to result from inactivation of tumor suppressor genes of the retinoblastoma family by a peptide known as the SV-40 large T-antigen. Several studies have documented the presence of SV-40 nucleic acids in a large proportion of mesothelioma cases (some of which did not have obvious asbestos exposure) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. As an example, one report examined 35 archival mesothelioma specimens and found that SV-40-like sequences were present in 86 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the possibility that technical factors (including laboratory contamination) can produce false-positive results suggestive of SV-40 infection also has been raised [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is possible but not unequivocally demonstrated that viral interference with tumor suppressor genes may play an important role in enabling the development of malignant mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/33\">",
"     33",
"    </a>",
"    ]. If this hypothesis is validated, novel strategies of vaccination to prevent mesothelioma, or molecular techniques to improve early diagnosis may become possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other etiologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of malignant pleural mesothelioma has associated in rare cases with intrapleural thorium dioxide (Thorotrast), and inhalation of other fibrous silicates, such as erionite. Epidemiologic studies of a region in central Anatolia (Turkey) with an abnormally high incidence of pleural mesothelioma (22 per 10,000 individuals over 25 years old) implicated routine household use of a locally ubiquitous silicate, zeolite, as a potential causative agent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1416281290\">",
"    <span class=\"h3\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivation of the nuclear deubiquitinase BAP1 is associated with malignant pleural mesothelioma. BAP1 appears to regulate key histones and transcription factors related to the development of tumors. In one study, inactivating mutations of BAP1 were found in about one-quarter of mesothelioma tumor tissues tested [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study, germline mutations in BAP1 were identified in two families with a high incidence of mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7622/abstract/36\">",
"     36",
"    </a>",
"    ]. Loss of BAP-1 may predispose to cancer after asbestos exposure; testing for mutations in this gene might eventually be used to identify patients at high risk who could be targeted for early intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=see_link\">",
"       \"Patient information: Asbestos exposure (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominant cause of asbestosis is inhalational exposure to asbestos. There is a latent period of approximately 30 to 40 years between exposure to asbestos and the development of mesothelioma. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asbestos exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recognition of the relationship between asbestos exposure and mesothelioma and other lung malignancies led to sharp restrictions in environmental exposure to asbestos. &nbsp;In the United States, these restrictions have lead to a gradual decrease in the total number of cases. In other areas, such as Great Britain, the number of cases continues to increase and the peak incidence has not yet been reached. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Asbestos exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to ionizing radiation to supradiaphragmatic fields in the treatment of malignancy (Hodgkin lymphoma, non-Hodgkin lymphoma, testicular cancer) has also been associated with a statistically significant increase in the risk of mesothelioma, although this accounts for only a small fraction of the mesothelioma cases diagnosed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A germline mutation in BAP1 has been associated with mesothelioma. (See",
"      <a class=\"local\" href=\"#H1416281290\">",
"       'Genetic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/1\">",
"      Teta MJ, Mink PJ, Lau E, et al. US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev 2008; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/2\">",
"      Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997; 145:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/3\">",
"      Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005; 92:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/4\">",
"      Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103:373S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/5\">",
"      Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin Proc 1988; 63:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/6\">",
"      Selikoff IJ, Hammond EC, Seidman H. Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 1980; 46:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/7\">",
"      Hansen J, de Klerk NH, Musk AW, Hobbs MS. Environmental exposure to crocidolite and mesothelioma: exposure-response relationships. Am J Respir Crit Care Med 1998; 157:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/8\">",
"      Pira E, Pelucchi C, Buffoni L, et al. Cancer mortality in a cohort of asbestos textile workers. Br J Cancer 2005; 92:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/9\">",
"      Hillerdal G. Malignant mesothelioma 1982: review of 4710 published cases. Br J Dis Chest 1983; 77:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/10\">",
"      Mossman BT. Carcinogenesis and related cell and tissue responses to asbestos: a review. Ann Occup Hyg 1994; 38:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/11\">",
"      Metintas M, Ozdemir N, Hillerdal G, et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999; 93:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/12\">",
"      Senyiit A, Babayiit C, G&ouml;kirmak M, et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000; 67:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/13\">",
"      Senyiit A, Bayram H, Babayiit C, et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the Southeast of Turkey: CT findings in 117 patients. Respiration 2000; 67:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/14\">",
"      Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002; 122:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/15\">",
"      Pan XL, Day HW, Wang W, et al. Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005; 172:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/16\">",
"      Gennaro V, Ugolini D, Viarengo P, et al. Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002). Eur J Cancer 2005; 41:2709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/17\">",
"      Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/18\">",
"      Tward JD, Wendland MM, Shrieve DC, et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/19\">",
"      Teta MJ, Lau E, Sceurman BK, Wagner ME. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer 2007; 109:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/20\">",
"      Travis LB, Foss&aring; SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/21\">",
"      Deutsch M, Land SR, Begovic M, et al. An association between postoperative radiotherapy for primary breast cancer in 11 National Surgical Adjuvant Breast and Bowel Project (NSABP) studies and the subsequent appearance of pleural mesothelioma. Am J Clin Oncol 2007; 30:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/22\">",
"      Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 1997; 80:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/23\">",
"      . Space elevators, tennis racquets, and mesothelioma. Lancet Oncol 2008; 9:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/24\">",
"      Takagi A, Hirose A, Nishimura T, et al. Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008; 33:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/25\">",
"      Poland CA, Duffin R, Kinloch I, et al. Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008; 3:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/26\">",
"      De Luca A, Baldi A, Esposito V, et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med 1997; 3:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/27\">",
"      Pass HI, Donington JS, Wu P, et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumor antigen DNA sequences. J Thorac Cardiovasc Surg 1998; 116:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/28\">",
"      Ramael M, Nagels J, Heylen H, et al. Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma. Eur Respir J 1999; 14:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/29\">",
"      McLaren BR, Haenel T, Stevenson S, et al. Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. Aust N Z J Med 2000; 30:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/30\">",
"      Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 2006; 1:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/31\">",
"      Pilatte Y, Vivo C, Renier A, et al. Absence of SV40 large T-antigen expression in human mesothelioma cell lines. Am J Respir Cell Mol Biol 2000; 23:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/32\">",
"      L&oacute;pez-R&iacute;os F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004; 364:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/33\">",
"      Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/34\">",
"      Gulmez I, Kart L, Buyukoglan H, et al. Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J 2004; 11:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/35\">",
"      Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011; 43:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7622/abstract/36\">",
"      Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4625 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7622=[""].join("\n");
var outline_f7_28_7622=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asbestos exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Carbon nanotubes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral oncogenes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other etiologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1416281290\">",
"      - Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16472?source=related_link\">",
"      Asbestosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/0/12298?source=related_link\">",
"      Cigarette smoking and other risk factors for lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32552?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29204?source=related_link\">",
"      Pathology of malignant pleural mesothelioma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/17/3347?source=related_link\">",
"      Patient information: Asbestos exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/41/28312?source=related_link\">",
"      Treatment approaches for localized malignant pleural mesothelioma and solitary fibrous tumor of the pleura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7623="AIDS-related cytomegalovirus neurologic disease";
var content_f7_28_7623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related cytomegalovirus neurologic disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7623/contributors\">",
"     Mark A Jacobson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7623/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7623/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7623/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/28/7623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) neurologic disease is an uncommon serious complication of AIDS, which can cause paralysis or rapidly fatal encephalitis. Prior to the availability of highly active antiretroviral therapy (HAART), CMV neurologic disease occurred in up to 2 percent of patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/1\">",
"     1",
"    </a>",
"    ], primarily in those with a CD4 T cell count below",
"    <span class=\"nowrap\">",
"     50/mm3.",
"    </span>",
"    However, the incidence of CMV neurologic disease has decreased since HAART became available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies support the hypothesis that CMV end-organ disease results from the hematogenous spread of CMV. The presence of CMV in blood (as measured by culture, CMV DNA amplification, or antigen detection) is a risk factor for the development of CMV disease in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/4\">",
"     4",
"    </a>",
"    ]. Studies in transplant recipients and patients with AIDS indicate that CD4-dependent, CMV-specific cytotoxic T lymphocyte activity is critical for preventing CMV replication and end-organ disease, and that impaired CD4 cell function or number is the key immune deficit that permits uncontrolled CMV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/5-7\">",
"     5-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most cases of CMV disease occur in patients with a CD4 cell count below",
"    <span class=\"nowrap\">",
"     50/mm3,",
"    </span>",
"    patients may be predisposed before such severe CD4 cell depletion. In a longitudinal study, patients with AIDS who subsequently developed CMV disease had lower T-cell proliferative responses to CMV, both early and late, compared to patients who did not develop disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/8\">",
"     8",
"    </a>",
"    ]. Genetic factors may contribute to this predisposition, since low responses to CMV were more common in those with HLA-B44 and HLA-DR7.",
"   </p>",
"   <p>",
"    CMV strains in the CSF of HIV-infected patients with encephalitis may differ significantly from those strains present in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/9\">",
"     9",
"    </a>",
"    ]. Phylogenetic analysis suggests possible viral recombination events, which may have an effect on neurovirulence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV neurologic disease can involve the brain, spinal cord, dorsal column nerve roots, or peripheral nerves. CMV inclusions have been identified in astrocytes, neurons, oligodendrocytes, and capillary endothelia of neural tissue. In the brain, CMV disease is characterized histologically by one of three patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microglial nodules that are dense aggregates of macrophages",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rod cells occurring in gray matter more often than white matter",
"     </li>",
"     <li>",
"      Focal parenchymal necrosis",
"     </li>",
"     <li>",
"      Ventriculoencephalitis with focal or diffuse destruction of the ependymal lining and periventricular tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the spinal cord, nerve roots, and peripheral nerves, CMV disease can cause subpial necrosis, axonal destruction, myelin degeneration, and a focal, polymorphonuclear necrotizing vasculitis of epineural arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of CMV neurologic disease are determined by anatomic location.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV encephalitis is essentially a disease of immunosuppressed subjects. In a review of 676 patients, 85 percent had AIDS, 12 percent had other causes of immunosuppression, and only 3 percent were immunocompetent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/10\">",
"     10",
"    </a>",
"    ]. CMV ventriculoencephalitis is a distinct entity found almost exclusively in patients with advanced HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CMV encephalitis, characterized by microglial nodules or focal parenchymal necrosis, tend to present with altered mental status that is difficult to distinguish clinically from the dementia caused by HIV itself [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/10\">",
"     10",
"    </a>",
"    ]. However, delirium, confusion, and focal neurologic abnormalities are more commonly associated with CMV-related than HIV-related dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with CMV ventriculoencephalitis present with the more acute onset of lethargy and confusion, often accompanied by cranial nerve involvement. CT scan or magnetic resonance imaging (MRI) of the brain typically shows periventricular enhancement in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CMV myelitis present with lower extremity weakness and hyperactive reflexes on neurologic examination. MRI of the spinal cord demonstrates no evidence of mass lesion, but enhancement of the cord is often present. Cerebrospinal fluid analysis may be unremarkable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Polyradiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CMV polyradiculopathy present with decreased lower extremity strength, decreased or absent reflexes, and, in some cases, urinary retention. The onset of symptoms usually occurs over a period of days to weeks. A myelogram or MRI reveals no mass lesions but may show that lower spinal nerve roots are thickened. Cerebrospinal fluid abnormalities, in particular a polymorphonuclear pleocytosis, are characteristic of this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with CMV peripheral nerve disease usually present with the syndrome of mononeuritis multiplex, consisting of multifocal or asymmetric sensory and motor deficits in the distribution of major peripheral or cranial nerves (especially the laryngeal nerves) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic criteria for CMV neurologic disease also vary with the site of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CMV encephalitis should be suspected in patients with advanced HIV disease (especially those with prior CMV disease in another site) who have a progressive change in mental status, delirium, rapidly progressive cognitive impairment, or signs and symptoms of brainstem injury. An MRI or contrast CT scan must be performed to exclude toxoplasmosis, lymphoma, progressive multifocal leukoencephalopathy, or other intracranial processes. Evidence of periventricular inflammation or meningeal enhancement helps support the diagnosis of CMV encephalitis but is not specific for the disease.",
"   </p>",
"   <p>",
"    Studies suggest that the detection of CMV DNA (eg, by polymerase chain reaction) or CMV antigen in the cerebrospinal fluid (CSF) is highly sensitive and specific for CMV neurologic disease involving the brain or cord [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. In one study of 13 patients with autopsy proven CMV infection of the brain, 12 had CMV DNA in the CSF compared to none of 11 without evidence of CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been several cases of immune reconstitution inflammatory syndrome (IRIS) reported after initiation of potent ART in which the clinical manifestation was encephalitis and the putative antigenic stimulus was central nervous system (CNS) CMV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Myelitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CMV myelitis should be suspected in patients with advanced HIV disease (especially those with prior CMV disease in another site) who have progressive lower extremity weakness and hyperactive reflexes on neurologic examination. An MRI or contrast CT scan of the spinal cord (or myelogram) should be performed to exclude mass lesions. Evidence of enhancement of the cord also helps support the presumptive diagnosis of CMV myelitis. A positive test for CMV DNA in the CSF also supports this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiculomyelopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of CMV radiculomyelopathy should be suspected in patients with advanced HIV disease (especially those with prior CMV disease in another site) who have progressive lower extremity weakness and decreased or absent reflexes on neurologic examination. An MRI or contrast CT scan of the spinal cord (or myelogram) should be performed to exclude mass lesions. Nerve root thickening, if present, supports the diagnosis of CMV myelitis. A lumbar puncture should be done for CSF analysis. In the appropriate clinical setting, a CSF polymorphonuclear pleocytosis with a negative CSF bacterial culture is very strong evidence for CMV radiculomyelopathy in a patient with AIDS who has a CD4 cell count below",
"    <span class=\"nowrap\">",
"     50/mm3.",
"    </span>",
"    A positive test for CMV DNA in the CSF also supports this diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mononeuritis multiplex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CMV mononeuritis multiplex should be suspected in patients with advanced HIV disease (especially those with prior CMV disease in another site) who have multifocal or asymmetric sensory and motor deficits in the distribution of major peripheral or cranial nerves (especially the laryngeal nerves). Biopsy of an involved peripheral nerve can confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knowledge of the outcome of CMV neurologic disease is limited to data from several small series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/13\">",
"     13",
"    </a>",
"    ]. Whether treated or not, median survival of patients with CMV neurologic disease was less than three months in the pre-HAART era. HAART could alter the natural history of CMV neurologic disease, even if such patients first initiate HAART after being diagnosed with CMV disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with extraocular CMV disease often have prior or concurrent CMV retinitis. As a result, any patient diagnosed with CMV neurologic disease not already known to have retinitis should undergo formal ophthalmologic screening for retinitis with such exams repeated at six month intervals until the patient's absolute CD4 count has been restored to &gt;100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    by antiretroviral therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacies and toxicities of approved treatments for CMV retinitis have been established by many randomized prospective trials. In contrast, there have been no prospective randomized trials of treatment for CMV neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few published case reports have demonstrated efficacy of three to six weeks of twice-daily intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    or both agents in combination (",
"    <a class=\"graphic graphic_table graphicRef80535 \" href=\"UTD.htm?23/41/24221\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/21\">",
"     21",
"    </a>",
"    ]. However, these intravenous therapies are expensive, toxic, and associated with complications related to indwelling lines; furthermore, shortages of intravenous ganciclovir have occurred intermittently. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     \"Ganciclovir: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    has not been tested in patients with other CMV end organ diseases, but is likely to have similar efficacy to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . Oral valganciclovir has been demonstrated to be effective therapy for CMV retinitis with no more toxicity than intravenous ganciclovir therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/22\">",
"     22",
"    </a>",
"    ]. Pharmacokinetically, in terms of ganciclovir area under the curve (ie, plasma drug levels integrated over time), oral valganciclovir at a dose of 900 mg is equivalent to intravenous ganciclovir at a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    For most patients, valganciclovir is the preferred drug to use for CMV end organ disease, because of its oral formulation, excellent bioavailability, lower cost, and lower risk of complications related to infusional therapy. &nbsp;",
"   </p>",
"   <p>",
"    Because rare cases of severe or fatal IRIS have been attributed to CMV infection of the central nervous system, clinicians may consider delaying the initiation of potent ART until the patient has demonstrated clinical improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of data from clinical trials, most neurologists who have expertise in AIDS-related CNS complications recommend combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    if the patient is able to take oral medication) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Side effects of intravenous ganciclovir and intravenous foscarnet",
"    </span>",
"    &nbsp;&mdash;&nbsp;These two drugs have different side effects (",
"    <a class=\"graphic graphic_table graphicRef70634 \" href=\"UTD.htm?4/25/4509\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia and thrombocytopenia have been the main toxicities of chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      therapy in patients with AIDS, and have been dose-limiting in 16 and 5 percent of patients, respectively. Ganciclovir-induced severe neutropenia usually can be reversed by the administration of granulocyte-colony stimulating factor [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"       \"Ganciclovir and valganciclovir: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reversible increases in serum creatinine (due to acute tubular necrosis) and symptoms of hypocalcemia during drug infusions (caused by transient,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      chelation of serum ionized calcium which can fall by 0.7 to 1.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [0.17 to 0.28",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      are the most serious toxicities of foscarnet, and have been dose-limiting in approximately 20 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Foscarnet can also cause transient hypomagnesemia by chelation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       \"Foscarnet: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additive inhibition of CMV can be achieved by combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    . A combined treatment regimen that has been tested in a prospective, controlled trial in patients with AIDS and relapsed CMV retinitis consisted of continuation of previous therapy plus induction with the other drug (either ganciclovir or foscarnet) for two weeks followed by standard maintenance doses of both ganciclovir (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and foscarnet (90",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    (HPMPC) is the first nucleotide, ie, nucleoside monophosphate, analogue to become available for use in clinical practice. The activity of cidofovir in vitro against CMV is 10- to 100-fold greater than that of other currently available anti-CMV drugs. In addition, because of cidofovir's prolonged antiviral effect, intermittent, intravenous administration is feasible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has caused serious, irreversible nephrotoxicity via dose-dependent proximal tubular cell injury. The initial manifestations of renal toxicity are proteinuria and increased serum creatinine concentrations; with continued treatment some patients have had a life-threatening Fanconi-like syndrome and renal failure. Saline hydration and high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    therapy (which can block cidofovir uptake by proximal renal tubular cells) have been given concomitantly with cidofovir in an attempt to reduce the risk of serious renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The oral probenecid regimen is 2 g three hours before the infusion and 1 g at both two and eight hours after the infusion. Because of a possible interaction between probenecid and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    to produce an increased rate of skin reactions, zidovudine should be withheld on the days of cidofovir administration.",
"   </p>",
"   <p>",
"    The exact incidence of nephrotoxicity is not known. In one series of 38 patients treated with either low or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    (3 and 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at two week intervals, respectively) for six to nine months, 10 developed an elevated serum creatinine concentration to 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (133",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or greater; and four (two in each group) had persistent elevations in this range [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to prevent progressive renal injury, dipstick analysis of the urine for protein and measurement of urinary protein excretion (estimated from a random urine total protein-to-creatinine ratio) and the serum creatinine concentration should be performed immediately before each",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .) The drug should be discontinued if the dipstick is 2+ or more, urine protein excretion increases significantly, or the serum creatinine rises by more than 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    over baseline. Other nephrotoxic drugs must be avoided when using cidofovir. With this management strategy, survival in cidofovir treatment trials has been similar to that reported in other trials of therapy for CMV retinitis.",
"   </p>",
"   <p>",
"    Nephrotoxicity or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    intolerance (eg, fever, nausea, vomiting, rash) have been treatment-limiting in approximately one-third to one-half of patients. Neutropenia, peripheral neuropathy, hypotony (abnormally low intraocular pressure), anterior uveitis, and alopecia also have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . In patients receiving protease inhibitor therapy, the risk of hypotony or uveitis may be as high as 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7623/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, monthly ophthalmologic examinations must be considered to be part of standard monitoring for cidofovir therapy and should include careful slit lamp examination of the anterior chamber and tonometry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4659968\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) neurologic disease is an uncommon serious complication of AIDS, which can cause paralysis or rapidly fatal encephalitis. Prior to the availability of potent antiretroviral therapy (ART), CMV neurologic disease occurred in up to 2 percent of patients with AIDS, primarily in those with a CD4 T cell count below",
"      <span class=\"nowrap\">",
"       50/mm3.",
"      </span>",
"      However, the incidence of CMV neurologic disease has decreased since ART became available. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies in transplant recipients and patients with AIDS indicate that CD4-dependent, CMV-specific cytotoxic T lymphocyte activity is critical for preventing CMV replication and end-organ disease, and that impaired CD4 cell function or number is the key immune deficit that permits uncontrolled CMV replication. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The symptoms of CMV neurologic disease are determined by anatomic location. Patients with CMV encephalitis tend to present with delirium while patients with CMV myelitis or polyradiculopathy may present with lower extremity weakness. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CMV-related disease is supported by documenting the presence of CMV infection in the cerebral spinal fluid through polymerase chain reaction (PCR) assays or antigen testing. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacies and toxicities of approved treatments for CMV retinitis have been established by many randomized prospective trials. In contrast, there have been no prospective randomized trials of treatment for CMV neurologic disease. For patients who can swallow, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      is the agent of choice. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because rare cases of severe or fatal IRIS have been attributed to CMV infection of the central nervous system, clinicians may consider delaying the initiation of potent ART until the patient has demonstrated clinical improvement. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/1\">",
"      Gallant JE, Moore RD, Richman DD, et al. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 1992; 166:1223.",
"     </a>",
"    </li>",
"    <li>",
"     Baril, L, Jouan, M, Caumes, E, et al. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients (abstract #I-31). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997; Toronto, Canada.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/3\">",
"      Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/4\">",
"      Shinkai M, Bozzette SA, Powderly W, et al. Utility of urine and leukocyte cultures and plasma DNA polymerase chain reaction for identification of AIDS patients at risk for developing human cytomegalovirus disease. J Infect Dis 1997; 175:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/5\">",
"      Rook AH, Manischewitz JF, Frederick WR, et al. Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. J Infect Dis 1985; 152:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/6\">",
"      Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/7\">",
"      Jacobson MA, Maecker HT, Orr PL, et al. Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. J Infect Dis 2004; 189:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/8\">",
"      Schrier RD, Freeman WR, Wiley CA, McCutchan JA. Immune predispositions for cytomegalovirus retinitis in AIDS. The HNRC Group. J Clin Invest 1995; 95:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/9\">",
"      Steininger C, Schmied B, Sarcletti M, et al. Cytomegalovirus genotypes present in cerebrospinal fluid of HIV-infected patients. AIDS 2005; 19:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/10\">",
"      Arribas JR, Storch GA, Clifford DB, Tselis AC. Cytomegalovirus encephalitis. Ann Intern Med 1996; 125:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/11\">",
"      Morgello S, Cho ES, Nielsen S, et al. Cytomegalovirus encephalitis in patients with acquired immunodeficiency syndrome: an autopsy study of 30 cases and a review of the literature. Hum Pathol 1987; 18:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/12\">",
"      Said G, Lacroix C, Chemouilli P, et al. Cytomegalovirus neuropathy in acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol 1991; 29:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/13\">",
"      McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 1995; 20:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/14\">",
"      Small PM, McPhaul LW, Sooy CD, et al. Cytomegalovirus infection of the laryngeal nerve presenting as hoarseness in patients with acquired immunodeficiency syndrome. Am J Med 1989; 86:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/15\">",
"      Revello MG, Percivalle E, Sarasini A, et al. Diagnosis of human cytomegalovirus infection of the nervous system by pp65 detection in polymorphonuclear leukocytes of cerebrospinal fluid from AIDS patients. J Infect Dis 1994; 170:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/16\">",
"      Arribas JR, Clifford DB, Fichtenbaum CJ, et al. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J Infect Dis 1995; 172:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/17\">",
"      Flood J, Drew WL, Miner R, et al. Diagnosis of cytomegalovirus (CMV) polyradiculopathy and documentation of in vivo anti-CMV activity in cerebrospinal fluid by using branched DNA signal amplification and antigen assays. J Infect Dis 1997; 176:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/18\">",
"      French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/19\">",
"      Aboulafia DM, Taylor L. Vacuolar myelopathy and vacuolar cerebellar leukoencephalopathy: a late complication of AIDS after highly active antiretroviral therapy-induced immune reconstitution. AIDS Patient Care STDS 2002; 16:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/20\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/21\">",
"      Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 1998; 158:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/22\">",
"      Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/23\">",
"      Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/24\">",
"      Jacobson MA, Gambertoglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991; 72:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/25\">",
"      Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992; 326:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/26\">",
"      Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/27\">",
"      Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996; 114:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/28\">",
"      Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997; 126:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/29\">",
"      Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7623/abstract/30\">",
"      Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3750 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-122.72.80.101-1C61674EA5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7623=[""].join("\n");
var outline_f7_28_7623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4659968\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Polyradiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Encephalitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Myelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiculomyelopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mononeuritis multiplex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Side effects of intravenous ganciclovir and intravenous foscarnet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4659968\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/41/24221\" title=\"table 1\">",
"      Drug monitoring CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4509\" title=\"table 2\">",
"      Complications Rx CMV retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=related_link\">",
"      Foscarnet: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=related_link\">",
"      Ganciclovir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7624="Simple silicosis CXR";
var content_f7_28_7624=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70007%7EPULM%2F79172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70007%7EPULM%2F79172&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simple silicosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a profusion of small rounded densities, predominantly within the upper lung zones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. E. L. Petsonk.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silicosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 357px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple nodules, 3 to 5 mm in diameter, with a bias for the upper lobes. Note calcification in some of the pulmonary nodules and the hilar lymph nodes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7624=[""].join("\n");
var outline_f7_28_7624=null;
var title_f7_28_7625="Interleukin-2 and other immunotherapies for advanced melanoma";
var content_f7_28_7625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interleukin-2 and other immunotherapies for advanced melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Jeffrey A Sosman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7625/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/28/7625/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H100471439\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the incidence of malignant melanoma is increasing, most cases are diagnosed at an early stage. In that setting, surgical excision is curative in most cases, and patients at high risk of developing metastatic disease may benefit from adjuvant therapy with interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with disseminated disease is a difficult problem. Approaches that have been shown to provide clinically important benefit for appropriately selected patients with stage IV melanoma include immunotherapy with high-dose interleukin-2 (IL-2) (",
"    <a class=\"graphic graphic_table graphicRef50225 graphicRef74203 \" href=\"UTD.htm?32/8/32910\">",
"     table 1A-B",
"    </a>",
"    ), immunotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (a monoclonal antibody targeting CTLA-4), and inhibition of the MAP kinase pathway with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17159?source=see_link\">",
"     vemurafenib",
"    </a>",
"    in patients whose tumors contain a V600 mutation in the BRAF gene. There are no randomized trials that compare immunotherapy with targeted therapy and there are no prospective data on the appropriate sequencing of these therapies.",
"   </p>",
"   <p>",
"    The use of IL-2 and various other immunotherapy approaches in the treatment of advanced melanoma will be reviewed here. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    (an anti-CTA-4 monoclonal antibody) and other immune checkpoint strategies, as well as an overview of the management of advanced melanoma are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100471453\">",
"    <span class=\"h1\">",
"     INTERLEUKIN-2",
"    </span>",
"    &nbsp;&mdash;&nbsp;IL-2 was first identified as a T cell growth factor in 1976. Recombinant IL-2 subsequently was shown to have potent, dose-dependent immunomodulatory and antitumor activity in a number of murine tumor models [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/2\">",
"     2",
"    </a>",
"    ]. These observations ultimately led to the development of high-dose IL-2 regimens for clinical use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552584207\">",
"    <span class=\"h2\">",
"     High-dose IL-2",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100471460\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies used high-dose bolus recombinant IL-2 (600,000 to 720,000 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    IV every eight hours on days 1 to 5 and 15 to 19 with a maximum of 28 doses per course) either alone or in combination with lymphokine-activated killer (LAK) cells.",
"   </p>",
"   <p>",
"    This regimen produced objective responses in 15 to 20 percent of patients, with complete responses in 4 to 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A retrospective analysis with extended follow-up of 270 patients treated with high-dose bolus IL-2 at the National Cancer Institute conducted between 1985 and 1993 demonstrated that this approach had a clinically significant benefit in a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Key findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The objective response rate was 16 percent, with a median duration of nine months (range 4 to 106+ months). Despite the low objective response rate, 59 percent of complete responders remained progression-free at seven years.",
"     </li>",
"     <li>",
"      At a minimum follow-up of six years, 44 percent of all responders remained alive, the vast majority disease- or progression-free. In addition, no patient responding for longer than 30 months had progressed, suggesting that some patients are \"cured\". Overall, 31 of the 270 patients (11 percent) were alive at last contact.",
"     </li>",
"     <li>",
"      Surgical resection of minimal residual disease may result in prolonged relapse-free survival in carefully selected patients who have a partial response after immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/7\">",
"       7",
"      </a>",
"      ]. Surgery is occasionally useful in those who relapse after achieving a complete response. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=see_link\">",
"       \"Surgical management of metastatic melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Responses were less frequent in patients with a poor performance status and those who had received prior systemic therapy. In contrast to results with IFNa, responses were seen with equal frequency in patients with visceral metastases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large tumor burdens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These durable complete remissions led to the approval of high-dose IL-2 for patients with metastatic melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100471489\">",
"    <span class=\"h3\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of high-dose IL-2 is limited by severe toxicity (",
"    <a class=\"graphic graphic_table graphicRef67823 graphicRef80320 \" href=\"UTD.htm?0/1/20\">",
"     table 2A-B",
"    </a>",
"    ). IL-2 is a potent inducer of proinflammatory cytokines such as IL-1, tumor necrosis factor alpha (TNFa), and IFN gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/8\">",
"     8",
"    </a>",
"    ]. These substances and others, including nitric oxide, appear to play a major role in IL-2 toxicity. The mechanism of IL-2 toxicity is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=see_link&amp;anchor=H15#H15\">",
"     \"Immunotherapy of renal cell carcinoma\", section on 'Toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Key side effects include hypotension, cardiac arrhythmias, pulmonary edema, fever, increased capillary permeability, and rarely death. Bacterial infection, particularly catheter-related sepsis, contributed significantly to the toxicity of IL-2 administration and was responsible for the six deaths reported in the early high-dose IL-2 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/5\">",
"     5",
"    </a>",
"    ]. Antibiotic prophylaxis has greatly reduced the incidence of catheter-related sepsis and dramatically improved the safety of this therapy.",
"   </p>",
"   <p>",
"    The severe multiorgan toxicity associated with high-dose IL-2 treatment has limited its use to patients with excellent organ function who are treated by experienced clinicians in specialized programs capable of providing the necessary intensive care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100471496\">",
"    <span class=\"h3\">",
"     Alternative regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lower doses of IL-2 and alternative routes of administration have been studied as ways to reduce the toxicity of IL-2 therapy. However, the overall response rate, quality, and duration of response appear to be superior with the high-dose bolus IL-2 regimen, although no randomized trials have been performed.",
"   </p>",
"   <p>",
"    Another approach to minimizing toxicity has been to integrate attenuated doses of IL-2 into regimens that include cytotoxic chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IFNa. These regimens have typically produced higher response rates and in some cases improved progression-free survival compared to chemotherapy alone, but no improvement in overall survival. Furthermore, durable responses were less frequent than seen with HD IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=see_link&amp;anchor=H100464929#H100464929\">",
"     \"Cytotoxic chemotherapy for metastatic melanoma\", section on 'Biochemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dose-dependency of IL-2 therapy is supported by the results of a phase II study, in which high-dose bolus IL-2 was given to patients who had progressed on or after treatment with biochemotherapy regimen containing lower doses of IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/10\">",
"     10",
"    </a>",
"    ]. Complete responses to treatment with high-dose bolus IL-2 were observed in 4 of 26 patients (15 percent), all of whom had failed to respond to the original IL-2-containing biochemotherapy regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552584402\">",
"    <span class=\"h3\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have looked at clinical parameters that might be useful in predicting a favorable outcome following treatment with high-dose IL-2:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of 374 patients treated with high dose IL-2 between 1988 and 1999 revealed a correlation between sites of metastatic disease and the objective response rate (54 percent for patients with cutaneous or subcutaneous metastasis compared to 12 percent for those with disease at other sites) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other analyses observed an improved response rate in patients with HLA-Cw7 phenotype, low pretreatment serum levels of C-reactive protein and IL-6, low plasma VEGF or fibronectin and normal serum LDH. The development of vitiligo or autoimmune thyroid dysfunction has been correlated with benefit from HD-IL-2 immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/11-14\">",
"       11-14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Newer methods such as gene expression profiling are being studied to select patients who are most likely to respond to IL-2, but this technology is not yet ready for routine clinical use [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these parameters has proven sufficiently predictive to be clinically useful in selecting patients for high-dose IL-2 therapy. Studies are ongoing to examine the role of tumor and host factors that impact the benefit of HD-IL-2. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H531559829\">",
"    <span class=\"h2\">",
"     Adoptive immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early animal models indicated that the activity of IL-2 was optimal when high doses were combined with IL-2 activated peripheral blood lymphocytes (LAK cells). However, randomized and sequential clinical trials comparing IL-2 plus LAK cells with high dose IL-2 alone failed to show sufficient benefit from the addition of LAK to justify their use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H531559836\">",
"    <span class=\"h3\">",
"     IL-2 plus TILs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efforts to improve upon the efficacy of high-dose IL-2 have combined IL-2 with autologous tumor infiltrating lymphocytes (TILs). Using this approach, objective responses were observed in 29 of 86 patients with metastatic melanoma (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/17\">",
"     17",
"    </a>",
"    ]. Responses were observed in some patients who had received prior IL-2, suggesting enhanced potency for the IL-2 plus TILs combination compared with IL-2 alone. However, only five responses were complete, and all but one of the partial responses lasted less than 10 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H531559843\">",
"    <span class=\"h3\">",
"     IL-2, TILs, and lymphodepletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In three subsequent sequential studies, chemotherapy with or without total body irradiation (TBI) was used to deplete lymphocytes in order to promote engraftment of tumor-reactive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemotherapy consisted of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for two days) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for five days). In the initial cohort of 43 patients, chemotherapy was followed by an infusion of TILs and then three days of high-dose IL-2. In the other two cohorts (each with 25 patients), TBI (either 2 Gy as a single dose or 4 Gy daily for three days) was given on the day after chemotherapy and before the TIL infusion. Autologous hematopoietic progenitor cell support was used in patients who received TBI.",
"   </p>",
"   <p>",
"    In the combined results from the 93 patients in these three studies, there were 52 objective responses (56 percent), including 20 complete responses (22 percent of the total cohort). Complete responses were ongoing at 37 to 82 months in 19 of the 20 responders, and the three- and five-year actuarial survival rates for patients achieving a complete response were 100 and 93 percent, respectively. The number of patients per cohort is small, and the studies sequential, making any comparison of those receiving the 12 Gy, 2 Gy or no TBI potentially misleading. These results must be confirmed by other centers, which will be difficult due to the complexity of the regimen.",
"   </p>",
"   <p>",
"    The use of adoptive cell therapy with TILs appears to have activity in patients with brain metastases. In a series of 17 patients with previously untreated brain metastases as well as extracranial disease who were treated with adoptive cell therapy using TILs, seven achieved a complete response in the brain and six had a partial response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1647693918\">",
"    <span class=\"h1\">",
"     IMMUNE CHECKPOINT INHIBITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     Ipilimumab",
"    </a>",
"    , an anti-CTLA-4 antibody, and other immune checkpoint inhibitors provide an important alternative immunotherapy strategy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464263289\">",
"    <span class=\"h1\">",
"     INTERFERON ALFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNa was the first recombinant cytokine used to treat metastatic melanoma. In various studies the dose of IFNa ranged from 10",
"    <span class=\"nowrap\">",
"     MU/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    to 50",
"    <span class=\"nowrap\">",
"     MU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    three times per week [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, the usefulness of IFNa for patients with metastatic melanoma is limited since tumor responses have largely been confined to patients with small volumes of cutaneous or soft tissue disease and the median duration of response was only about four months [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, these responses led to the use of high-dose IFNa regimens in the adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=see_link\">",
"     \"Adjuvant immunotherapy for melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100471510\">",
"    <span class=\"h1\">",
"     OTHER CYTOKINES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552587176\">",
"    <span class=\"h2\">",
"     Interleukin-21",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-21 (IL-21) is a cytokine that is produced by activated CD4 T cells and natural killer T cells. Preclinical studies indicate that IL-21 has multiple functions including stimulation of B cell differentiation, T cells, and NK and CD8 T cell cytotoxic functions.",
"   </p>",
"   <p>",
"    IL-21 was evaluated in a phase II study in patients with nonbulky metastatic melanoma who had not received prior therapy for metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/24\">",
"     24",
"    </a>",
"    ]. A total of 40 patients were evaluated on one of three schedules. Nine confirmed partial responses were observed (22 percent) and 16 patients (40 percent) had stable disease. The median progression-free survival was 4.3 months, and median overall survival was 12 months.",
"   </p>",
"   <p>",
"    Additional clinical trials combining IL-21 with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    are in progress [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702566996\">",
"    <span class=\"h2\">",
"     Interleukin-12",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-12 (IL-12) increases immunity by inducing a number of cytokines from dendritic cells and has activity in a various animal models of melanoma. Phase I and II trials using systemic IL-12 in patients with melanoma and other malignancies showed activity but were associated with excessive toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Subsequently, phase I studies using intralesional administration of the IL-12 gene into tumor in patients with advanced melanoma has mitigated toxicity and had activity at remote metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/28\">",
"     28",
"    </a>",
"    ]. While further development of IL-12 has been slow due to limited drug availability, a number of investigations are exploring various delivery methods for IL-12 and further assessment of its potential as a vaccine adjuvant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552587183\">",
"    <span class=\"h2\">",
"     Granulocyte-macrophage-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro, granulocyte-macrophage (GM) colony-stimulating factor (CSF) activates macrophages to become cytotoxic for human melanoma cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/29\">",
"     29",
"    </a>",
"    ], and it mediates the proliferation, maturation, and migration of dendritic cells, which play an important role in the induction of T cell mediated immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/30\">",
"     30",
"    </a>",
"    ]. Although a phase II study suggested that overall survival was improved in patients with completely resected stage III or IV melanoma, a cooperative group phase III trial (ECOG 4697) did not demonstrate an improvement in overall survival compared with placebo or a peptide vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552587190\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other cytokines (TNFa, IFN gamma, IL-4, IL-6) have been evaluated in patients with metastatic melanoma and are essentially inactive when given systemically [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TNFa in combination with IFN gamma may have utility in isolated limb perfusion of locoregionally recurrent extremity melanomas, particularly when given with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/32\">",
"     32",
"    </a>",
"    ]. TNFa is approved for this indication in Europe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=see_link&amp;anchor=H12#H12\">",
"     \"Cutaneous melanoma: Management of in transit metastases\", section on 'Isolated limb perfusion or infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552586250\">",
"    <span class=\"h1\">",
"     ENHANCEMENT OF CELLULAR IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of cellular immunity begins when T cells recognize peptide fragments of intracellular proteins that are expressed on the surface of antigen presenting cells (APCs) bound to specific MHC molecules. This interaction requires the presence of a costimulatory molecule (B7). This activation results in an upregulation of cytotoxic T-lymphocyte antigen 4 (CTLA-4), which competes for binding with B7, causing a negative feedback inhibition of T cell activation.",
"   </p>",
"   <p>",
"    This understanding of cellular immunity has led to the identification of new targets for promoting potent immune responses in patients with melanoma. The results with immumonoclonal antibodies that target CTLA4 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"     ipilimumab",
"    </a>",
"    ) or other immune regulatory checkpoints are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"     \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H702567106\">",
"    <span class=\"h2\">",
"     HLA-B7 gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy approaches in melanoma have primarily focused upon injecting genes that will enhance the immunogenicity of melanoma. In animal models, immunization with tumor cells transfected with the genes for granulocyte-macrophage colony stimulating factor (GM-CSF), the T cell costimulatory molecule (B7-1), the alloantigen HLA-B7 (allovectin 7), or interleukin-6 (IL-6) gene protected animals from subsequent challenge by wild-type tumor cells and in some instances induced regression of established tumor cells. In man, a phase I study of a plasmid coding for interleukin-12 has produced regression of injected lesions and in two cases distant subcutaneous metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive human experience comes from clinical studies using allovectin-7. Allovectin-7 is a plasmid that encodes the alloantigen HLA-B7 and beta-2 microglobulin, and is delivered in a lipid system [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Allovectin-7 is administered intralesionally to induce a proinflammatory response.",
"   </p>",
"   <p>",
"    Final results of phase II studies that included 133 patients were presented at ASCO in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with visceral metastases (other than lung) were excluded. Overall, 15 patients (12 percent) had an objective response, with a median duration of 13 months. Treatment was well tolerated, and no grade 3 or 4 adverse events were associated with treatment. A phase III trial in which patients are randomly assigned to allovectin-7 or to systemic chemotherapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    has completed enrollment and results are pending (NCT00395070) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with liver or brain metastases were excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1656045064\">",
"    <span class=\"h2\">",
"     OncoVEXGM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Production of granulocyte macrophage colony stimulating factor GM-CSF within tumor has been used in an effort to enhance cellular immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. This approach has used an oncolytic herpes simplex virus expressing granulocyte macrophage colony stimulating factor (OncoVEXGM-CSF), which is injected directly into tumor.",
"   </p>",
"   <p>",
"    In a phase II study of 50 patients with stage IIIc or IV disease, the overall response rate was 26 percent (eight complete and five partial responses) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/37\">",
"     37",
"    </a>",
"    ]. The observed responses appeared to be durable in both injected and uninjected lesions; overall survival in this study was 58 and 52 percent at one and two years, respectively. A phase III trial, comparing OncoVEXGM-CSF with systemic subcutaneous injections of GM-CSF alone, has recently completed accrual (NCT00769704) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100469004\">",
"    <span class=\"h1\">",
"     VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of melanoma-specific vaccines comprised of defined antigens, whole melanoma cells, or melanoma cell lysates, have been investigated either in the adjuvant setting or in patients with metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552585445\">",
"    <span class=\"h2\">",
"     T cell antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of T cell antigens have been identified in patients with melanoma, and these are the basis for ongoing research with vaccine given alone or in combination with IL-2.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MART-1, gp100, and tyrosinase, and their specific peptides are recognized by cytotoxic T lymphocytes (CTLs) capable of lysing autologous and allogeneic melanoma cells that express HLA-A2.1 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a phase III trial, 185 patients with metastatic melanoma were randomly assigned to high-dose IL-2 given alone every three weeks or in combination with the gp100 peptide vaccine [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/41\">",
"       41",
"      </a>",
"      ]. The objective response rate based upon a centralized review was significantly increased with the combination compared with IL-2 alone (16 versus 6 percent). There were eight complete responses (9 percent) in the combination arm, but only one (1 percent) among those treated with IL-2 alone. There was a trend toward increased overall survival (median 17.8 versus 11.1 months, p=0.06), although the trial was not adequately powered to assess a survival endpoint. The clinical significance of this finding is uncertain considering the relatively poor response rate in patients treated with HD IL-2 alone and the alteration in the schedule of IL-2 administration to an every three week treatment. However, it is the first phase III trial to successfully demonstrate that a vaccine might improve IL-2 based immunotherapy of melanoma. Of note, this same vaccine did not improve the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      in a phase III trial, perhaps suggesting that the impact of a vaccine may depend on the coadministered immunotherapy. &nbsp;",
"     </li>",
"     <li>",
"      MAGE-3 contains both HLA-A1 and HLA-2.1 restricted CTL epitopes and is expressed on approximately 70 percent of melanoma samples. In combination with an adjuvant, MAGE-3 induced both a specific antibody response and a cellular immune response in patients with advanced melanoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/42\">",
"       42",
"      </a>",
"      ]. More recent work demonstrated that gene expression profiling can identify specific markers that are associated with an improved clinical response to the MAGE-3 vaccine. In a phase II EORTC study, the presence of this gene signature was associated with a significantly prolonged time to treatment failure (10 versus 2 months in those without the characteristic gene signature) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A phase III trial has been initiated in which patients with completely resected stage III melanoma are randomly assigned to placebo or a MAGE-A3 vaccine (NCT00796445) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/45\">",
"       45",
"      </a>",
"      ]. In this trial, all patients must have expression of the MAGE-A3 gene in their resected lymph node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H552585758\">",
"    <span class=\"h2\">",
"     Ganglioside vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gangliosides are sialic acid-containing glycosphingolipids that are overexpressed on the cell surface of melanomas. Gangliosides can induce antibody responses; in addition, the de novo presence of antibody to GM2 ganglioside (ie, without vaccination) has been associated with prolonged survival in patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administering GM2 with BCG or combining it with the keyhole limpet hemocyanin (KLH) hapten and using a QS21 adjuvant is effective in inducing an antibody response to GM2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. However, two large phase III trials did not demonstrate a survival benefit when a vaccine using GM2-KLH with the saponin adjuvant QS21 was used in an adjuvant setting [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100469011\">",
"    <span class=\"h2\">",
"     Whole cell or cell lysate vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several vaccines have been prepared from allogeneic melanoma cell lines, hapten-modified autologous tumor cells, or allogeneic melanoma cell line lysates [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/53-58\">",
"     53-58",
"    </a>",
"    ]. Based upon promising phase II results, two of these vaccines (CancerVax, Melacine) were studied in phase III trials in patients with stage III or resected stage IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, neither of these randomized trials showed any benefit from these vaccine approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H100469074\">",
"    <span class=\"h2\">",
"     Other vaccine approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other vaccine approaches that are being evaluated in patients with stage III or stage IV melanoma include dendritic cells, which can be pulsed with cell lysates and use as a vaccine to enhance T lymphocyte responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], and DNA vaccines that encode either an entire gene or the antigenic epitope to stimulate a cellular immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7625/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional study will be required to determine whether these approaches may have a role in the management of patients with melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       \"Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=see_link\">",
"       \"Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464263980\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose bolus interleukin (IL)-2 is associated with prolonged survival in a minority of carefully selected patients and may actually result in cure. (See",
"      <a class=\"local\" href=\"#H100471460\">",
"       'Efficacy'",
"      </a>",
"      above.) However, this treatment is associated with severe and potentially life threatening cardiovascular, respiratory, and infectious complications. (See",
"      <a class=\"local\" href=\"#H100471489\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients without a V600 BRAF mutation, we recommend immunotherapy rather than chemotherapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link&amp;anchor=H863137387#H863137387\">",
"       \"Overview of the management of advanced melanoma\", section on 'Choice and sequence of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For good performance status patients who have access to appropriate specialized programs, we suggest treatment with high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. (See",
"      <a class=\"local\" href=\"#H100471453\">",
"       'Interleukin-2'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with a poor performance status or untreated brain metastases who thus are not candidates for high dose IL-2, we recommend immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H327750098#H327750098\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Previously untreated patients'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a good performance status, we suggest immunotherapy rather than targeted therapy as the initial systemic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link&amp;anchor=H863137387#H863137387\">",
"       \"Overview of the management of advanced melanoma\", section on 'Choice and sequence of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have access to appropriate specialized programs, we suggest high-dose IL-2 rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Ipilimumab is an alternative when IL-2 is not available or appropriate. (See",
"      <a class=\"local\" href=\"#H100471453\">",
"       'Interleukin-2'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link&amp;anchor=H175769012#H175769012\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\", section on 'Ipilimumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a V600 BRAF mutation and a poor performance status, we suggest targeted therapy rather than immunotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Immunotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/52/19270?source=see_link\">",
"       ipilimumab",
"      </a>",
"      is an alternative. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=see_link\">",
"       \"Molecularly targeted therapy for metastatic melanoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=see_link\">",
"       \"Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/1\">",
"      Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1996; 14:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/2\">",
"      Rosenberg SA, Mul&eacute; JJ, Spiess PJ, et al. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/3\">",
"      Dutcher JP, Creekmore S, Weiss GR, et al. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 1989; 7:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/4\">",
"      Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/5\">",
"      Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/6\">",
"      Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000; 6 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/7\">",
"      Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol 2006; 16:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/8\">",
"      Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/9\">",
"      McDermott DF, Atkins MB. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J Clin Oncol 2007; 25:3791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/10\">",
"      Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007; 25:3802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/11\">",
"      Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001; 19:3477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/12\">",
"      Joseph RW, Sullivan RJ, Panka GD, et al. Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. J Clin Oncol 2010; 28:15s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/13\">",
"      Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am 1998; 12:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/14\">",
"      Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009; 27:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/15\">",
"      Wang E, Miller LD, Ohnmacht GA, et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 2002; 62:3581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/16\">",
"      Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/17\">",
"      Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/18\">",
"      Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17:4550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/19\">",
"      Hong JJ, Rosenberg SA, Dudley ME, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010; 16:4892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/20\">",
"      Dummer R, Garbe C, Thompson JA, et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/21\">",
"      Agarwala SS, Kirkwood JM. Interferons in melanoma. Curr Opin Oncol 1996; 8:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/22\">",
"      Creagan ET, Ahmann DL, Frytak S, et al. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 1986; 70:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/23\">",
"      Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am 1998; 12:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/24\">",
"      Petrella TM, Tozer R, Belanger K, et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 2012; 30:3396.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ (Accessed on August 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/26\">",
"      Alatrash G, Hutson TE, Molto L, et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 2004; 22:2891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/27\">",
"      Younes A, Pro B, Robertson MJ, et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004; 10:5432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/28\">",
"      Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/29\">",
"      Nawrocki S, Murawa P, Malicki J, et al. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000; 74:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/30\">",
"      Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995; 154:5851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/31\">",
"      Lawson DH, Lee SJ, Tarhini AA, et al. Phase III cooperative group study of yeast-derived granulocyte macrophage colony stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III_IV melanoma. J Clin Oncol 2010; 28:612s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/32\">",
"      Li&eacute;nard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res 1999; 9:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/33\">",
"      Richards JM, Bedikian A, Gonzalez R. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and desing of phase 3 registration trial. J Clin Oncol 2005; 23:720s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/34\">",
"      Gonzalez R, Hutchins L, Nemunaitis J, et al. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006; 16:521.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical trials database file://www.clinicaltrials.gov/ (Accessed on April 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/36\">",
"      Hu JC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12:6737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/37\">",
"      Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health, Clinical Trials Database. file://www.clinicaltrials.gov/ (Accessed on September 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/39\">",
"      Sosman JA, Carrillo C, Urba WJ, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008; 26:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/40\">",
"      Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/41\">",
"      Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/42\">",
"      Vantomme V, Dantinne C, Amrani N, et al. Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 2004; 27:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/43\">",
"      Louahed J, Gruselle O, Gaulis S. Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE - A3 immunotherapeutic in metastatic melanoma patients. J Clin Oncol 2008; 26:494s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/44\">",
"      Kruit WH, Suciu S, Dreno B. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group. J Clin Oncol 2008; 26:494s.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database file://www.clinicaltrials.gov/ (Accessed on April 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/46\">",
"      Jones PC, Sze LL, Liu PY, et al. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst 1981; 66:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/47\">",
"      Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A 1987; 84:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/48\">",
"      Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/49\">",
"      Helling F, Zhang S, Shang A, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/50\">",
"      Livingston PO, Adluri S, Helling F, et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/51\">",
"      Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/52\">",
"      Eggermont AM, Suiciu S, Rutkowski P. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: Final results of study EORTC 18961. J Clin Oncol 2010; 28:612s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/53\">",
"      Morton DL, Hoon DS, Nizze JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci 1993; 690:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/54\">",
"      DiFronzo LA, Gupta RK, Essner R, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002; 20:3242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/55\">",
"      Lotem M, Peretz T, Drize O, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer 2002; 86:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/56\">",
"      Berd D, Maguire HC Jr, Schuchter LM, et al. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 1997; 15:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/57\">",
"      Berd D, Sato T, Maguire HC Jr, et al. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004; 22:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/58\">",
"      Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/59\">",
"      Morton DL, Mozzillo N, Thompson JF. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol 2007; 25:474s.",
"     </a>",
"    </li>",
"    <li>",
"     Sosman JA. Unpublished data. March 9, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/61\">",
"      Ross M, Camacho LH, Hersh EM. Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial. J Clin Oncol 2007; 25:478s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/62\">",
"      L&oacute;pez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J Clin Oncol 2009; 27:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7625/abstract/63\">",
"      Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15:2044.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15407 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7625=[""].join("\n");
var outline_f7_28_7625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H464263980\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100471439\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100471453\">",
"      INTERLEUKIN-2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552584207\">",
"      High-dose IL-2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100471460\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100471489\">",
"      - Toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H100471496\">",
"      - Alternative regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H552584402\">",
"      - Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H531559829\">",
"      Adoptive immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H531559836\">",
"      - IL-2 plus TILs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H531559843\">",
"      - IL-2, TILs, and lymphodepletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1647693918\">",
"      IMMUNE CHECKPOINT INHIBITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464263289\">",
"      INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100471510\">",
"      OTHER CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552587176\">",
"      Interleukin-21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702566996\">",
"      Interleukin-12",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552587183\">",
"      Granulocyte-macrophage-CSF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552587190\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H552586250\">",
"      ENHANCEMENT OF CELLULAR IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H702567106\">",
"      HLA-B7 gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1656045064\">",
"      OncoVEXGM-CSF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H100469004\">",
"      VACCINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552585445\">",
"      T cell antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H552585758\">",
"      Ganglioside vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100469011\">",
"      Whole cell or cell lysate vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H100469074\">",
"      Other vaccine approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464263980\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/15407\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/15407|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/61/8157\" title=\"table 1A\">",
"      Melanoma 7th TNM staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/20/35149\" title=\"table 1B\">",
"      Melanoma 7th TNM stage group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/8/1165\" title=\"table 2A\">",
"      Mgmt interleukin 2 toxicity I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/51/27452\" title=\"table 2B\">",
"      Mgmt interleukin 2 toxicity II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44711?source=related_link\">",
"      Adjuvant immunotherapy for melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2506?source=related_link\">",
"      Advanced melanoma: anti-CTLA-4 antibodies and other immune checkpoint strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27081?source=related_link\">",
"      Cutaneous melanoma: Management of in transit metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8328?source=related_link\">",
"      Cytotoxic chemotherapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/14/12522?source=related_link\">",
"      Immunotherapy of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19944?source=related_link\">",
"      Molecularly targeted therapy for metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/8/39042?source=related_link\">",
"      Patient information: Melanoma treatment; advanced or metastatic melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/8/2183?source=related_link\">",
"      Surgical management of metastatic melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7626="Treatment and complications of diabetic ketoacidosis in children";
var content_f7_28_7626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and complications of diabetic ketoacidosis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7626/contributors\">",
"     George S Jeha, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Morey W Haymond, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/28/7626/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/28/7626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic ketoacidosis (DKA) is the leading cause of morbidity and mortality in children with type 1 diabetes mellitus (DM), ranging from 0.15 percent to 0.31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In addition, DKA also can occur in children with type 2 DM; this presentation is most common among youth of African-American descent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/4-8\">",
"     4-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of DKA in children, which is based upon the large collective experience of children with type 1 DM, will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef76460 \" href=\"UTD.htm?23/4/23629\">",
"     table 1",
"    </a>",
"    ). There is limited experience in the management and outcomes of DKA in children with type 2 DM, although the same principles should apply. The clinical manifestations and diagnosis of DKA in children and the pathogenesis of DKA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consensus statements from the European Society for Paediatric",
"    <span class=\"nowrap\">",
"     Endocrinology/Lawson",
"    </span>",
"    Wilkins Pediatric Endocrine Society",
"    <span class=\"nowrap\">",
"     (ESPE/LWPES)",
"    </span>",
"    in 2004, the American Diabetes Association (ADA) in 2006, and the International Society for Pediatric and Adolescent Diabetes (ISPAD) in 2007 defined the following biochemical criteria for the diagnosis of DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperglycemia, defined as a blood glucose of &gt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      <strong>",
"       AND",
"      </strong>",
"     </li>",
"     <li>",
"      Metabolic acidosis, defined as a venous pH &lt;7.3",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a plasma bicarbonate &lt;15",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      (15",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These abnormalities are accompanied by disturbances in fluid and electrolyte balance, resulting in volume depletion and mild to moderate serum hyperosmolality. The clinical manifestations of DKA are related to the degree of hyperosmolality, volume depletion, and severity of acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach and principles of management are the same for all children with DKA regardless of the severity of DKA. However, based upon the severity of presentation, the clinician should determine the appropriate clinical setting in which to treat the child. As an example, a mild presentation of DKA without vomiting may be managed in an ambulatory setting under close supervision and monitoring by an experienced diabetes team. On the other hand, a patient with severe DKA will need a level of care found in a pediatric intensive care unit.",
"   </p>",
"   <p>",
"    The clinician must individualize the treatment plan based on the child's physical and laboratory findings, and treatment will need to be adjusted over time for each child. No protocol or formula should be blindly used in the management of DKA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assessment of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical and laboratory findings have been used by the authors to estimate the severity of DKA at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic status &mdash; Severe neurologic compromise at presentation is a poor prognostic indicator, primarily because such patients are at increased risk for developing cerebral edema during therapy. This was illustrated in a retrospective multicenter study of 61 children with DKA and cerebral edema; all patients who either died or survived in a persistent vegetative state presented with Glasgow coma score &le;7 (score of 6 to 7 includes an abnormal or absent purposeful response to pain) (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Glasgow coma score is not adequately sensitive to identify patients early in the course of developing cerebral edema. As a result, we suggest additional monitoring of all patients for the development of more subtle signs of cerebral edema (",
"      <a class=\"graphic graphic_table graphicRef53017 \" href=\"UTD.htm?3/3/3132\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cerebral edema'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Acid-base status &mdash; The venous pH and serum bicarbonate concentration directly reflect the severity of the acidosis (",
"      <a class=\"graphic graphic_table graphicRef72608 \" href=\"UTD.htm?11/13/11483\">",
"       table 4",
"      </a>",
"      ). The respiratory rate also may be helpful, because the magnitude of the respiratory compensation is directly related to the severity of the acidosis.",
"      <br/>",
"      <br/>",
"      The anion gap is a useful measure of the severity of the metabolic acidosis (because it reflects both ketosis and lactic acidosis). A high anion gap may also reflect decreased renal perfusion, which limits ketoacid excretion. Alternatively, measurement of plasma beta-hydroxybutyrate may be available and permits direct monitoring of the degree of ketoacidemia.",
"     </li>",
"     <li>",
"      Volume status &mdash; Children with moderate or severe DKA are estimated to present with a 7 to 10 percent fluid deficit, as discussed below. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fluid and electrolyte deficits and repletion'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Duration of symptoms &mdash; A long duration of symptoms, as well as depressed level of consciousness or compromised circulation, is evidence of severe DKA and should prompt close monitoring for potential complications of DKA, such as cerebral edema [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-11\">",
"       9-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Moderate and severe DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying principles of management are to administer insulin and to correct the fluid and electrolyte abnormalities of metabolic acidosis, hypovolemia, potassium, and perhaps phosphate depletion. During initial therapy, the patient should be carefully monitored for signs of cerebral edema. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fluid and electrolyte deficits and repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies estimating water and electrolyte losses in DKA were conducted in the 1940s and 1950s. Most included adults, but one was a detailed study of a 10-year-old female [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The data from the available studies are consistent with the following average losses in severe DKA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Water &mdash; 70 (range 30 to 100)",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"     </li>",
"     <li>",
"      Sodium &mdash; 5 to 13",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"     </li>",
"     <li>",
"      Potassium &mdash; 6 to 7",
"      <span class=\"nowrap\">",
"       meq/kg",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult to clinically assess the degree of dehydration in children presenting with DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/18\">",
"     18",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     ESPE/LWPES",
"    </span>",
"    consensus recommended that initial fluid management of children with moderate or severe DKA be based upon the assumption that patients present with a 7 to 10 percent fluid deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This recommendation is consistent with the above studies that assessed fluid and electrolyte losses. However, fluid replacement should be performed gradually, as discussed below.",
"   </p>",
"   <p>",
"    Urinary losses from the glucose osmotic diuresis (due to osmotic action of glucose and ketones in the urine) and gastrointestinal losses from vomiting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea, if present, result in extracellular volume depletion. At the time of presentation, clinical estimates of the extracellular fluid volume deficit in moderate to severe DKA are usually in the range of 7 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10,18\">",
"     9,10,18",
"    </a>",
"    ]. Hypovolemic shock is a rare occurrence in DKA. The patient in shock should be evaluated for other causes of shock.",
"   </p>",
"   <p>",
"    Evaluation of the degree of dehydration in the child with DKA is difficult even for the experienced clinician. Many of the clinical findings used to assess volume status are unreliable, such as the condition of the patient's oropharynx, which is almost always dry because of hyperventilation and mouth breathing. Skin turgor is also frequently unreliable because the fluid losses are from both the extracellular and intracellular spaces. &nbsp;",
"   </p>",
"   <p>",
"    In addition, the degree of extracellular fluid loss is in part masked because hyperglycemia results in a shift of water from the intracellular to the extracellular fluid compartment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/18\">",
"     18",
"    </a>",
"    ]. This effect is rapidly reversed with insulin therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated urine specific gravity, which is a common sign of volume depletion in children, cannot be used as a measure of hypovolemia in patients with DKA because glucose and, to a lesser degree, ketones raise the specific gravity. Elevations in the blood urea nitrogen and hematocrit remain useful laboratory studies to confirm hypovolemia in DKA and to follow its correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30197583\">",
"    <span class=\"h3\">",
"     Fluid repletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of initial volume expansion are [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To restore the effective circulating volume by replacing sodium and water loss",
"     </li>",
"     <li>",
"      To restore glomerular filtration rate to enhance clearance of ketones and glucose from the blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most experts recommend accomplishing the volume expansion gradually and with isotonic fluids, because these approaches might reduce the risk for cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. The evidence underlying this possible association is weak and conflicting. In one clinical study in children, high volume of fluid administration during the first four hours of treatment was one of several risk factors for cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/19\">",
"     19",
"    </a>",
"    ]. However, several other clinical studies failed to show such an association [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Nonetheless, gradual correction of the deficit and the use of isotonic fluids seems prudent. In patients who are not markedly hypovolemic, this approach may even result in earlier reversal of the acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30197649\">",
"    <span class=\"h4\">",
"     Initial volume expansion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume and rate of administration depend upon the effective circulating volume. Fluid repletion in moderate to severe DKA is usually begun with an infusion of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over one hour. If and only if the effective circulating volume is still compromised, an additional infusion of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    can be given over the next hour. We generally do not give more than 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    in total boluses unless the patient's cardiovascular status is compromised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial volume expansion should be with a solution which is near isotonic, such as isotonic saline [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In our practice, the initial volume expansion is done with Ringer's Lactate. Subsequently, the deficit is corrected with Ringer's lactate to which potassium has been added. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Metabolic acidosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30197713\">",
"    <span class=\"h4\">",
"     Subsequent fluid administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the child is hemodynamically stable, subsequent volume expansion should be given more slowly. The rate of fluid administration should not exceed 1.5 to 2 times the maintenance rate and should not include urinary losses. The hourly rate of fluid administration should never exceed two times the maintenance rate (about 3000",
"    <span class=\"nowrap\">",
"     cc/m2/day)",
"    </span>",
"    unless there is objective evidence of shock; excessive fluids may increase the risk for cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Cerebral edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The solution used for this ongoing volume repletion should initially consist of isotonic saline (normal saline or lactated Ringers) for approximately four to six hours. For most patients, 40",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of potassium salts should be added to the solution to correct the total body potassium deficit. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Serum potassium'",
"    </a>",
"    below.) In our practice, we use lactated Ringers to which 35",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    of potassium is added (20",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    and 15",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     potassium chloride",
"    </a>",
"    ) throughout the period of rehydration.",
"   </p>",
"   <p>",
"    After the first four to six hours of treatment, some clinicians will reduce the sodium concentration to not less than one-half isotonic, provided that the serum sodium concentration is rising appropriately as the serum glucose concentration falls, and that the patient's circulatory and mental status are stable. The choice between one-half isotonic and isotonic saline depends on the patient's circulatory status and the rise in serum sodium as the hyperglycemia is corrected. Inclusion of potassium salts in the replacement fluid should be based on serum potassium concentrations.",
"   </p>",
"   <p>",
"    Once the ketoacidosis is predominantly cleared and oral fluids are permitted, hourly rates of fluid administration can be liberalized to achieve full hydration over 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The rate over the first 24 hours should not exceed 1.5 to 2 times the usual rate of administration of maintenance fluid. Based upon body surface area, the total fluid intake should be no greater than 3500",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    for 24 hours, including the initial fluid bolus as well as any oral intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the initial fluid bolus is complete, an insulin infusion is begun at a rate of 0.1",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    per hour [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A lower dose of 0.05",
"    <span class=\"nowrap\">",
"     unit/kg",
"    </span>",
"    per hour may be used initially in younger children who may be more sensitive to insulin. Do not give an initial bolus of insulin. A study with a case-control design suggests that the risk of cerebral edema is decreased by delaying insulin administration for one hour or more after initiation of fluid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The insulin can be mixed in one-half isotonic saline and administered in a syringe infusion pump to control the rate of insulin administration. The solution should be concentrated as much as possible, because the tubing and syringe can bind insulin, and should be flushed through the tubing of the insulin infusion syringe. As an example, 50 units of short-acting (\"regular\") insulin are added to 50 mL of one-half isotonic saline, providing 1 unit per mL of infusate. The syringe is then \"piggybacked\" into the patient's indwelling intravenous catheter as close as possible to the venous site.",
"   </p>",
"   <p>",
"    Within 60 minutes, steady state serum insulin levels are achieved (100 to 200",
"    <span class=\"nowrap\">",
"     microU/mL),",
"    </span>",
"    which offset insulin resistance, suppress glucose and ketone production, and stimulate peripheral glucose and ketone metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In addition, volume expansion will lower the serum glucose by dilution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=see_link\">",
"     \"Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most patients, the hyperglycemia corrects before the ketoacidosis. Normalization of the serum glucose concentration may not always be accompanied with an improvement in the metabolic acidosis. The insulin infusion rate should only be reduced when the ketoacidosis is corrected. If the ketoacidosis persists, the patient should be reassessed. Possible explanations are severe insulin resistance due to infection, incorrect preparation of the insulin infusion, and decreased insulin delivery due to adhesion of insulin to tubing. We recommend preparing a new insulin syringe for the pump to rule out the possibility of an erroneous dilution of insulin. The insulin dose in such patients usually needs to be increased.",
"   </p>",
"   <p>",
"    When the serum glucose concentration decreases to 250 to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9 to 16.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the intravenous fluid infusion should be changed to 5 percent dextrose in isotonic saline or lactated Ringer's solution. This allows continued administration of insulin, which is often necessary to correct the residual ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/11\">",
"     11",
"    </a>",
"    ]. If the serum glucose falls below 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before complete resolution of the ketoacidosis, the concentration of dextrose in the intravenous solution should be increased to up to 10 to 12.5 percent.",
"   </p>",
"   <p>",
"    Some institutions use a \"two bag system\" to adjust the dextrose concentration of the intravenous fluids between 0 and 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. In this technique, two bags of the selected saline solution are prepared, one of which contains 10 percent dextrose and the other 0 percent dextrose. By adjusting the relative rates of fluid administration from each bag, the rate of fluid administration can be maintained constant, while the variable rate of glucose infusion can be achieved to respond to changes in the patient's serum glucose concentrations.",
"   </p>",
"   <p>",
"    The purpose of adding dextrose to the intravenous solution is to prevent hypoglycemia while continuing to administer insulin to correct ketoacidosis. In our practice, we establish steady rates of insulin and intravenous fluids during the first six to eight hours of insulin therapy, which allows for a gradual decrease in serum glucose concentrations (about 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    per hour or 3 to 5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    per hour). Once the serum glucose reaches 200 to 300",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    dextrose is added to the IV solution (usually as 5 percent dextrose) to permit the continued insulin administration necessary to clear the ketoacidosis while minimizing the risk of hypoglycemia. In younger patients with increased insulin sensitivity it may be necessary to decrease the insulin infusion rate to 0.05",
"    <span class=\"nowrap\">",
"     units/kg/hour",
"    </span>",
"    as long as the ketoacidosis continues to improve. For patient safety reasons, it is advisable to keep serum glucose concentrations around 150 to 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3 to 11.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for younger children; or 100 to 150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in older children (5.5 to 8.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    before switching to subcutaneous insulin.",
"   </p>",
"   <p>",
"    In unusual circumstances, and especially if facilities to administer intravenous insulin are not readily available, subcutaneous or intramuscular insulin can be used as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, with subcutaneous administration, the absorption of insulin may be inconsistent, particularly in the setting of volume depletion and secondary sympathetic activation which can decrease local perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Serum sodium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial sodium concentration will depend on the net sodium and water losses prior to hospitalization, the degree of hyperglycemia and the degree of lipemia (severe hyperlipidemia causes pseudohyponatremia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It must be kept in mind that diabetic ketosis is a form of hypertonic dehydration, and care must be taken in rehydrating the patient. During rehydration, the clinician must serially assess the serum sodium and employ anticipatory planning in the fluid replacement plan. Reversing the hyperglycemia with fluid expansion and insulin administration will lower the plasma osmolality, cause water to move from the extracellular fluid into the cells, and raise the serum sodium concentration. Failure of the serum sodium to rise appropriately could be an early sign that the patient is at risk for cerebral edema, as suggested by a few studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. A causal association between the rate or concentration of sodium administered during treatment for DKA and the development of cerebral edema has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the serum sodium fails to rise appropriately, consideration should be given to increasing the sodium concentration in the infused fluids and decreasing their rate of administration. The patient should be carefully monitored for early signs of cerebral edema. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Cerebral edema'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"     \"Cerebral edema in children with diabetic ketoacidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we measure serum sodium hourly for the first three to four hours and then every two hours, to assess the anticipated changes of serum sodium described above. When clinically appropriate, the frequency of measurement can be reduced to every four to six hours.",
"   </p>",
"   <p>",
"    With appropriate replacement of fluids and electrolytes in a child who is otherwise improving, the serum sodium concentration should gradually increase. The expected rise in serum sodium (Na) attributable to the decrease in serum glucose can be calculated according to the following formula [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;Corrected serum Na = Measured serum Na +",
"    <span class=\"nowrap\">",
"     [&Delta;SG",
"    </span>",
"    &divide; 42]",
"   </p>",
"   <p>",
"    where",
"    <span class=\"nowrap\">",
"     &Delta;SG",
"    </span>",
"    is the increment above normal in the serum glucose concentration (in",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    The",
"    <span class=\"nowrap\">",
"     &Delta;SG",
"    </span>",
"    should be divided by 2.3 if measured in",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    Thus, serum Na should rise by approximately 2.4",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    for every 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    fall in plasma glucose. Some clinicians plot the corrected sodium concentration on a nomogram (",
"    <a class=\"graphic graphic_figure graphicRef64779 \" href=\"UTD.htm?16/17/16671\">",
"     figure 1",
"    </a>",
"    ) to facilitate tracking of changes in serum sodium during insulin treatment and to help identify patients in whom the serum sodium does not rise appropriately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Serum potassium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both renal and gastrointestinal losses can contribute to an often marked degree of potassium depletion in DKA. These losses will tend to produce hypokalemia. On the other hand, the combination of insulin deficiency, which impairs potassium entry into the cells, and hyperosmolality, which pulls water and potassium out of the cells, tend to raise the serum potassium. Ketoacidosis itself appears to have little effect on transcellular potassium movement. The evidence supporting this conclusion and why this might occur are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=see_link\">",
"     \"Potassium balance in acid-base disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of these counteracting effects, the serum potassium at the time of presentation can be normal, increased, or decreased. Regardless of the initial level, insulin therapy drives potassium into cells, resulting in a fall in the serum potassium concentration. Thus, potassium replacement will almost always be required within one to two hours of the initiation of fluid and insulin therapy in children with DKA who do not have renal failure. In our experience, most patients present with potassium levels in the normal or high range. After initial IV expansion, the potassium concentration generally falls into the normokalemic or mildly hypokalemic range. It is uncommon for patients to present with hypokalemia before fluid expansion. However, should this be the case, more aggressive potassium replacement is indicated.",
"   </p>",
"   <p>",
"    Optimal therapy varies with the initial serum potassium. Regardless of the regimen, the serum potassium should be carefully monitored during therapy. In addition, electrocardiographic monitoring is recommended in patients with either hypokalemia or hyperkalemia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is normokalemic, potassium replacement should be given with the start of insulin therapy (eg, adding 40",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      of potassium to the saline solution), as insulin will reduce the serum potassium.",
"     </li>",
"     <li>",
"      If the patient is markedly hypokalemic, potassium replacement should be started",
"      <strong>",
"       immediately",
"      </strong>",
"      , using an initial potassium concentration of 40",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      concurrent with volume expansion. The serum potassium levels should be monitored hourly and the replacement adjusted as needed. The insulin infusion should be delayed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      given at a reduced rate until the serum potassium is in the normal range.",
"     </li>",
"     <li>",
"      If the patient is hyperkalemic, potassium replacement should be initiated when the serum potassium falls to normal and after verifying urine production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potassium replacement is usually given as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     potassium chloride",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"     Potassium phosphate",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/18/5412?source=see_link\">",
"     potassium acetate",
"    </a>",
"    also have been used. Potassium replacement therapy should continue with intravenous insulin and fluid therapy and the serum potassium should be carefully monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Metabolic acidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin and fluid repletion leads to partial correction of the acidosis seen in DKA. Insulin promotes the metabolism of ketoacid anions, resulting in the generation of bicarbonate, and stops the ongoing production of new ketoacids. Improved tissue perfusion corrects any lactic acidosis that might be present.",
"   </p>",
"   <p>",
"    Ketoacid anions have been called \"potential bicarbonate,\" because their metabolism following the administration of insulin results in the generation of bicarbonate and reversal of the acidosis. However, bicarbonate cannot be regenerated from the ketoacid anions that were excreted in the urine.",
"   </p>",
"   <p>",
"    As a result of the urinary loss of \"potential bicarbonate,\" almost all patients with DKA (except those advanced renal failure) develop a usually mild normal anion gap acidosis (also known as \"non-gap acidosis\") during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Suppose, for example, that a patient has a serum bicarbonate of 8",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    an anion gap of 24",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    and a ketone body concentration of 12 mM. Administration of insulin will convert all 12 mM of ketoacid anion back into bicarbonate; however, the serum bicarbonate concentration may only rise by about 6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    (to 14",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    with the remainder replenishing the cell and bone buffer stores. At this point, the patient has a metabolic acidosis with a normal anion gap of 12. If no ketoacid anions had been excreted in the urine (as in a dialysis patient), then insulin therapy would have returned both the anion gap and serum bicarbonate concentration to baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=see_link\">",
"     \"The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is substantial evidence that bicarbonate therapy should not be used in DKA. Controlled trials both in adults and children have been unable to demonstrate any clinical benefit from the routine administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/56/41862?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In addition to lack of benefit, there are potential risks from bicarbonate therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Excessive bicarbonate therapy to a near-normal pH can lead to a rapid rise in PCO2 (since there is less of an acidemic stimulus to hyperventilation), resulting in a paradoxical fall in cerebral pH as the lipid-soluble CO2 rapidly crosses the blood-brain barrier [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of alkali may slow the rate of recovery of ketosis. One report evaluating seven patients found that the three who received bicarbonate had a rise in plasma ketoacid levels during bicarbonate infusion and also had a six-hour delay in improvement of ketosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/42\">",
"       42",
"      </a>",
"      ]. Studies in animals suggested that bicarbonate therapy acts by increasing hepatic ketogenesis.",
"     </li>",
"     <li>",
"      The administration of bicarbonate can lead to a post-treatment metabolic alkalosis after insulin-induced metabolism of ketoacid anions results in the regeneration of bicarbonate and spontaneous correction of most of the metabolic acidosis.",
"     </li>",
"     <li>",
"      Bicarbonate therapy may be a risk factor for cerebral edema [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cerebral edema'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The rapid correction of acidosis with bicarbonate therapy may result in hypokalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The additional sodium load can further increase the degree of hyperosmolality before decreasing glucose levels with fluid and insulin therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these reasons, we do not use bicarbonate for the treatment of DKA unless other complications occur, such as cardiac arrest. However, the ADA and",
"    <span class=\"nowrap\">",
"     ESPE/LWPES",
"    </span>",
"    consensus statements suggest that highly selected patients may benefit from cautious alkali therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-11\">",
"     9-11",
"    </a>",
"    ], in particular, patients with severe acidemia (arterial pH &lt;6.90) in whom decreased cardiac contractility and vasodilatation can further impair tissue perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cellular phosphate depletion is a common problem in uncontrolled diabetes mellitus. The serum phosphate concentration may initially be normal or elevated due to movement of phosphate out of the cells. As with hyperkalemia, the phosphate depletion is rapidly unmasked following the institution of insulin therapy, frequently leading to hypophosphatemia. Plasma phosphate levels frequently fall as low as 1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    during treatment of DKA, without evident adverse consequences.",
"   </p>",
"   <p>",
"    There have been concerns that low plasma phosphate levels could result in metabolic disturbances with particular concern about the erythrocyte 2,3-diphosphoglycerate concentration and its effect on tissue oxygenation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/43\">",
"     43",
"    </a>",
"    ]. However, hypophosphatemia has not been shown to affect tissue oxygenation in adult patients with DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/44\">",
"     44",
"    </a>",
"    ] and randomized trials of phosphate replacement in adults have failed to show clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous phosphate administration may induce hypocalcemia and hypomagnesemia, and is generally not necessary or sufficient to replace the total body phosphate deficit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/47\">",
"     47",
"    </a>",
"    ]. Therefore, we do not suggest phosphate replacement to address asymptomatic mild hypophosphatasemia. The phosphate deficit will be repleted after the DKA resolves and the patient resumes eating.",
"   </p>",
"   <p>",
"    The main indication for phosphate therapy is a serum phosphate concentration less than 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.32",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    When phosphate is given, careful monitoring of the serum calcium and magnesium is required [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In this case, phosphate can be given by using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/58/4006?source=see_link\">",
"     potassium phosphate",
"    </a>",
"    salts instead of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/17/11542?source=see_link\">",
"     potassium chloride",
"    </a>",
"    to provide potassium replacement. It is also reasonable to use potassium phosphate salts for part of the potassium replacement for patients with lesser degrees of hypophosphatemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Phosphate depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of the child with DKA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of DKA requires close monitoring of the patient's clinical condition including changes in vital signs, neurologic status, fluid status, and metabolic state (eg, serum electrolytes, glucose, urea nitrogen, hematocrit, and venous pH) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This should be accompanied by appropriate documentation that is easy to follow and is able to detect clinical changes that require medical attention.",
"   </p>",
"   <p>",
"    It is the authors' experience that a flow sheet of laboratory values and clinical parameters allows better visualization and evaluation of the clinical picture throughout treatment of DKA. Emphasis should be placed on the hourly evaluation of the patient's fluid status, changes in osmolality, glucose, and electrolytes, and changes in the patient's mental and neurologic status as outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor blood glucose hourly during the initial 4 to 6 hours of fluid and insulin therapy. Subsequently, the frequency of blood glucose measurements should be dictated by the rapidity of correction of the metabolic acidosis and hyperglycemia. If capillary samples are obtained for the measurement of blood glucose, they should initially be compared to a venous measurement. These measurements should be used to adjust the rate of dextrose infusion by adjusting the dextrose concentration in the fluids (but not the rate of fluid or insulin infusion), until the metabolic acidosis due to ketosis is predominantly cleared. It is important to remember that insulin and fluids will not correct a metabolic acidosis due to hyperchloremia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electrolytes and venous pH should be initially evaluated hourly for the first three to four hours and then every two hours. When clinically appropriate, the frequency of measurement can be reduced to every four to six hours. These measurements are used to assess the anticipated changes of sodium, potassium, bicarbonate, and anion gap. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical parameters including heart rate, respiratory rate, blood pressure, oxygen saturation, and neurologic status should be monitored continuously. In patients with severe DKA or altered mental status, frequent neurologic examinations are recommended. Monitor for warning signs and symptoms of cerebral edema including headache, inappropriate decrease in heart rate, recurrence of vomiting, changes in neurologic status, rising blood pressure, and decreased oxygen saturation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cerebral edema'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Initiate electrocardiographic monitoring in patients with severe DKA or abnormal serum potassium concentrations. Evaluate the tracing for changes characteristic of hyperkalemia or hypokalemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H10#H10\">",
"       \"ECG tutorial: Miscellaneous diagnoses\", section on 'Electrolyte abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measure and record fluid input and output accurately. If the patient is neurologically impaired or it is difficult to ascertain urine output, a urine catheter should be placed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Discontinuing the insulin infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin infusion should continue at 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour until the following conditions are met [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum anion gap reduced to normal (12 &plusmn; 2",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"     </li>",
"     <li>",
"      Venous pH is &gt;7.30 or serum HCO3 is &gt;15",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      Plasma glucose &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Tolerating oral intake",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During treatment for DKA, correction of the ketoacidosis does not necessarily result in complete correction of the metabolic acidosis. The residual acidosis is associated with a normal anion gap that is due to urinary loss of ketoacid anions which, as noted above, represents the loss of \"potential bicarbonate.\" In this setting, insulin therapy will have no further effect on the acidosis. Thus, a persistent normal anion gap acidosis is not a contraindication for switching the patient to subcutaneous insulin, since there are no circulating ketoacids remaining. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Metabolic acidosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The first subcutaneous injection should be given at an appropriate interval to allow for absorption prior to stopping insulin infusion. The onset of rapid-acting insulin (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/40/14982?source=see_link\">",
"     insulin lispro",
"    </a>",
"    ) is approximately 15 minutes, whereas that of short-acting (regular) insulin is 30 to 60 minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Borderline DKA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with borderline DKA (venous pH &gt;7.30, serum bicarbonate &gt;16",
"    <span class=\"nowrap\">",
"     meq/L),",
"    </span>",
"    no neurologic impairment, and estimated volume deficit less than 3 percent (",
"    <a class=\"graphic graphic_table graphicRef72608 \" href=\"UTD.htm?11/13/11483\">",
"     table 4",
"    </a>",
"    ) who are not vomiting may be managed in an ambulatory setting under the supervision of an experienced medical team. However, hospitalization may appropriate for young children (eg, &lt;5 years of age) because of their sensitivity to insulin as compared with older children, and because of their increased risk for cerebral edema. Children of any age should be treated in hospital if the home environment does not provide close supervision and monitoring.",
"   </p>",
"   <p>",
"    Commercially available fluids for oral hydration such as Rehydralyte (75",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    sodium and 20",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    potassium) can be used alone or in combination with initial parenteral fluid repletion. These fluids contain dextrose 2.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (2.5 percent).",
"   </p>",
"   <p>",
"    A short-acting insulin (eg, recombinant modified human insulin, also known as \"regular\" insulin) can be given subcutaneously and repeated at three to six hour intervals as needed. The dose is adjusted depending upon the response.",
"   </p>",
"   <p>",
"    Close monitoring of serum electrolytes, glucose, and fluid balance is required. The patient should be transferred to an appropriate inpatient setting if there is an inadequate response or the clinical condition deteriorates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPLICATIONS AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported mortality rates for DKA are consistent in developed countries, ranging from 0.15 to 0.51 percent in national population studies in Canada, the United Kingdom, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/1-3,48\">",
"     1-3,48",
"    </a>",
"    ]. Cerebral edema accounts for the majority of deaths (60 to 90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/22,49\">",
"     22,49",
"    </a>",
"    ]. Other causes include aspiration pneumonia, multiple organ failure, gastric perforation, and traumatic hydrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral edema occurs in 0.3 to 1 percent of children with DKA and has a high mortality rate of 21 to 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-11,48\">",
"     9-11,48",
"    </a>",
"    ]. Children who are younger, newly diagnosed with diabetes, or who present with severe acidosis or dehydration are at the greatest risk. Cerebral edema generally develops during treatment for DKA, and current protocols were strongly influenced by efforts to reduce risks. Nonetheless, cerebral edema can occur in optimally managed cases, and early identification and treatment of the problem is essential. Up to 20 percent of cases of cerebral edema occur before the initiation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All children should be carefully monitored for early signs of cerebral edema throughout the course of treatment for DKA (",
"    <a class=\"graphic graphic_table graphicRef53017 \" href=\"UTD.htm?3/3/3132\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/12\">",
"     12",
"    </a>",
"    ]. The Glasgow coma scale can be used to evaluate for neurologic dysfunction, but may not be adequately sensitive to identify children early enough for effective intervention. More subtle neurological symptoms such as new onset or intensifying headache, altered consciousness, recurrent vomiting, age-inappropriate incontinence, irritability, or lethargy may be valuable as earlier indicators of cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/11,50\">",
"     11,50",
"    </a>",
"    ]. Changes detectable by head computed tomography occur late in the development of cerebral edema. Therefore, the decision to treat should be based on clinical evaluation. Imaging may be useful to exclude other causes of neurological deterioration, but should not delay treatment.",
"   </p>",
"   <p>",
"    The pathophysiology, risk factors, diagnosis, and treatment of cerebral edema in children with DKA are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"     \"Cerebral edema in children with diabetic ketoacidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6903862\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary evidence suggests that DKA may be associated with subsequent neurocognitive dysfunction, even in patients who did not have clinical evidence of cerebral edema [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. There is insufficient information to determine if these effects are directly related to DKA or are a marker for other complications of type 1 diabetes, such as recurrent hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=see_link&amp;anchor=H12#H12\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Neurologic sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Venous thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with DKA appear to be at increased risk for deep venous thrombosis, particularly in association with femoral central venous catheter placement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. It has been suggested that this may in part be due to a prothrombotic state associated with DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with DKA who present with an altered state of consciousness and vomiting are at increased risk for aspiration. Placement of a nasogastric tube should be performed and stomach contents emptied. If necessary, intubation also should be performed to protect the airway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cardiac arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias may be seen with either hypokalemia or hyperkalemia. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Serum potassium'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pancreatic enzyme elevations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild elevations in serum amylase and lipase are seen in about 40 percent of children with DKA, and are also common in adults with DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/56\">",
"     56",
"    </a>",
"    ]. In most cases, this does not reflect acute pancreatitis. The diagnosis of acute pancreatitis should be based on clinical findings and confirmed by CT scan. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum amylase and lipase'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts should be made to prevent DKA both before and after the diagnosis of diabetes mellitus has been established. Methods that may promote earlier diagnosis of diabetes include increasing awareness of both public and healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/57\">",
"     57",
"    </a>",
"    ] and identifying high-risk individuals through family history, genetic, and immunologic screening [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among children with known diabetes, a comprehensive diabetes program may reduce the rates of DKA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Identification of the patients at greatest risk for recurrence and placement in a comprehensive program may decrease the rate of DKA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Worsening glycemic control often precedes the onset of DKA. Thus, the patient or caregiver should be taught to increase the frequency of testing blood glucose and measuring urine or blood ketones when the patient's blood glucose is greater than 240",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=see_link\">",
"       \"Patient information: Diabetic ketoacidosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the above discussion regarding the treatment of DKA and is consistent with consensus statements from the American Diabetes Association, European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes (",
"    <a class=\"graphic graphic_table graphicRef76460 \" href=\"UTD.htm?23/4/23629\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obtain initial laboratory studies (electrolytes, serum glucose, venous pH, urea nitrogen, hematocrit, and a urine analysis; and blood beta-hydroxybutyrate if available). Continue to monitor blood glucose hourly during the initial 4 to 6 hours of fluid and insulin therapy. Subsequently, the frequency of blood glucose measurements should be dictated by the rapidity of correction of the metabolic acidosis and hyperglycemia. Measure electrolytes and venous pH hourly for the first three to four hours, then every two hours thereafter until the metabolic acidosis is cleared. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend careful evaluation and monitoring for signs and symptoms of cerebral edema in all children undergoing treatment for DKA (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Specific signs of increased intracranial pressure and changes detectable by head computed tomography often occur too late for effective intervention. Early symptoms that may indicate cerebral edema include new onset or intensifying headache, altered consciousness, and recurrent vomiting, ultimately progressing to bradycardia and opisthotonic posturing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cerebral edema'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=see_link\">",
"       \"Cerebral edema in children with diabetic ketoacidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Initiate fluid repletion using an isotonic crystalloid solution at a rate of 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in the first hour. Repeat this regimen if the effective circulatory volume remains compromised. (See",
"      <a class=\"local\" href=\"#H30197583\">",
"       'Fluid repletion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial fluid bolus is complete, an insulin infusion is begun at a rate of 0.1",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      per hour. A lower dose of 0.05",
"      <span class=\"nowrap\">",
"       unit/kg",
"      </span>",
"      per hour may be used initially in younger children who may be more sensitive to insulin. An insulin bolus should NOT be given. Consider subcutaneous insulin when the venous pH is &gt;7.30, the serum bicarbonate is &gt;16",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      or the anion gap is normal. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Add 5 percent dextrose to the intravenous fluid when the serum glucose decreases to 250-300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9 to 16.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      If the serum glucose falls below 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      before resolution of the ketoacidosis, increase the concentration of dextrose in the intravenous fluid up to 10 to 12.5 percent. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insulin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After the initial fluid bolus, ongoing volume repletion should initially consist of isotonic saline (normal saline or lactated Ringers) at a rate that should not exceed 1.5 to 2 times maintenance and should not include urinary losses. The rate of intravenous fluid administration should be calculated to fully replete the patient's estimated fluid deficit over 48 hours. (See",
"      <a class=\"local\" href=\"#H30197713\">",
"       'Subsequent fluid administration'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      After the first 4 to 6 hours of treatment, the sodium concentration may be reduced to not less than one-half isotonic saline, provided that the patient's circulatory status is stable and the serum sodium concentration is rising appropriately as the serum glucose concentration falls. The choice between one-half isotonic and isotonic saline depends on the patient's circulatory status and the rise in serum sodium as the hyperglycemia is corrected. The goal should be a slow decrease in serum osmolality to normal. (See",
"      <a class=\"local\" href=\"#H30197713\">",
"       'Subsequent fluid administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial sodium concentrations will depend on the degree of net sodium and water losses prior to hospitalization, the degree of hyperglycemia and the degree of lipemia (pseudohyponatremia). With the correction of hyperglycemia, serum sodium concentrations should rise (and should be permitted to rise). Note that an increase in free water intake that attenuates or prevents the expected rise in serum sodium concentration may increase the risk of cerebral edema. During rehydration, the clinician should serially assess the serum sodium and employ anticipatory planning in fluid replacement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Serum sodium'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with DKA require potassium repletion, but the timing varies with serum potassium concentration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serum potassium'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the patient is normokalemic, potassium replacement should be given with the start of insulin therapy; starting concentrations of 40",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"      KCl are reasonable.",
"     </li>",
"     <li>",
"      If the patient is hypokalemic, potassium replacement should be started immediately, as insulin will further reduce the serum potassium. The insulin infusion should be delayed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      given at a reduced rate until the serum potassium level is in the normal range. One approach is to give potassium 40",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      (40",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      added to normal saline and infused at a rate of 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over the first hour.",
"     </li>",
"     <li>",
"      If the patient is hyperkalemic, potassium replacement should be initiated when the serum potassium falls to normal and after documentation of urine production.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend NOT treating with bicarbonate (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, a few highly selected patients may benefit from cautious alkali therapy, including those with severe acidosis (arterial pH &lt;6.90), particularly those with impairment of cardiac contractility or life-threatening hyperkalemia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/28/7626/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Metabolic acidosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/1\">",
"      Levitsky L. Death from diabetes (DM) in hospitalized children (1970-1988). Pediatr Res 1991; 29:A195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/2\">",
"      Edge JA, Ford-Adams ME, Dunger DB. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child 1999; 81:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/3\">",
"      Curtis JR, To T, Muirhead S, et al. Recent trends in hospitalization for diabetic ketoacidosis in ontario children. Diabetes Care 2002; 25:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/4\">",
"      Pinhas-Hamiel O, Dolan LM, Zeitler PS. Diabetic ketoacidosis among obese African-American adolescents with NIDDM. Diabetes Care 1997; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/5\">",
"      Scott CR, Smith JM, Cradock MM, Pihoker C. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatrics 1997; 100:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/6\">",
"      Banerji MA. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--\"Flatbush diabetes\". J Pediatr Endocrinol Metab 2002; 15 Suppl 1:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/7\">",
"      Sellers EA, Dean HJ. Diabetic ketoacidosis: a complication of type 2 diabetes in Canadian aboriginal youth. Diabetes Care 2000; 23:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/8\">",
"      Neufeld ND, Raffel LJ, Landon C, et al. Early presentation of type 2 diabetes in Mexican-American youth. Diabetes Care 1998; 21:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/9\">",
"      Dunger DB, Sperling MA, Acerini CL, et al. ESPE/LWPES consensus statement on diabetic ketoacidosis in children and adolescents. Arch Dis Child 2004; 89:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/10\">",
"      Dunger DB, Sperling MA, Acerini CL, et al. European Society for Paediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society consensus statement on diabetic ketoacidosis in children and adolescents. Pediatrics 2004; 113:e133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/11\">",
"      Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/12\">",
"      Wolfsdorf J, Craig ME, Daneman D, et al. Diabetic ketoacidosis. Pediatr Diabetes 2007; 8:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/13\">",
"      Edge JA, Roy Y, Bergomi A, et al. Conscious level in children with diabetic ketoacidosis is related to severity of acidosis and not to blood glucose concentration. Pediatr Diabetes 2006; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/14\">",
"      Marcin JP, Glaser N, Barnett P, et al. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr 2002; 141:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/15\">",
"      DARROW DC, PRATT EL. Retention of water and electrolyte during recovery in a patient with diabetic acidosis. J Pediatr 1952; 41:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/16\">",
"      Atchley DW, Loeb RF, Richards DW, et al. ON DIABETIC ACIDOSIS: A Detailed Study of Electrolyte Balances Following the Withdrawal and Reestablishment of Insulin Therapy. J Clin Invest 1933; 12:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/17\">",
"      BUTLER AM, TALBOT NB. Metabolic studies in diabetic coma. Trans Assoc Am Physicians 1947; 60:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/18\">",
"      Koves IH, Neutze J, Donath S, et al. The accuracy of clinical assessment of dehydration during diabetic ketoacidosis in childhood. Diabetes Care 2004; 27:2485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/19\">",
"      Edge JA, Jakes RW, Roy Y, et al. The UK case-control study of cerebral oedema complicating diabetic ketoacidosis in children. Diabetologia 2006; 49:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/20\">",
"      Hom J, Sinert R. Evidence-based emergency medicine/critically appraised topic. Is fluid therapy associated with cerebral edema in children with diabetic ketoacidosis? Ann Emerg Med 2008; 52:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/21\">",
"      Brown TB. Cerebral oedema in childhood diabetic ketoacidosis: is treatment a factor? Emerg Med J 2004; 21:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/22\">",
"      Glaser N, Barnett P, McCaslin I, et al. Risk factors for cerebral edema in children with diabetic ketoacidosis. The Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. N Engl J Med 2001; 344:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/23\">",
"      Felner EI, White PC. Improving management of diabetic ketoacidosis in children. Pediatrics 2001; 108:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/24\">",
"      Adrogu&eacute; HJ, Barrero J, Eknoyan G. Salutary effects of modest fluid replacement in the treatment of adults with diabetic ketoacidosis. Use in patients without extreme volume deficit. JAMA 1989; 262:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/25\">",
"      Luzi L, Barrett EJ, Groop LC, et al. Metabolic effects of low-dose insulin therapy on glucose metabolism in diabetic ketoacidosis. Diabetes 1988; 37:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/26\">",
"      Schade DS, Eaton RP. Dose response to insulin in man: differential effects on glucose and ketone body regulation. J Clin Endocrinol Metab 1977; 44:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/27\">",
"      Grimberg A, Cerri RW, Satin-Smith M, Cohen P. The \"two bag system\" for variable intravenous dextrose and fluid administration: benefits in diabetic ketoacidosis management. J Pediatr 1999; 134:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/28\">",
"      Fisher JN, Shahshahani MN, Kitabchi AE. Diabetic ketoacidosis: low-dose insulin therapy by various routes. N Engl J Med 1977; 297:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/29\">",
"      Della Manna T, Steinmetz L, Campos PR, et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005; 28:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/30\">",
"      Soler NG, FitzGerald MG, Wright AD, Malins JM. Comparative study of different insulin regimens in management of diabetic ketoacidosis. Lancet 1975; 2:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/31\">",
"      Duck SC, Weldon VV, Pagliara AS, Haymond MW. Cerebral edema complicating therapy for diabetic ketoacidosis. Diabetes 1976; 25:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/32\">",
"      Duck SC, Wyatt DT. Factors associated with brain herniation in the treatment of diabetic ketoacidosis. J Pediatr 1988; 113:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/33\">",
"      Harris GD, Fiordalisi I, Harris WL, et al. Minimizing the risk of brain herniation during treatment of diabetic ketoacidemia: a retrospective and prospective study. J Pediatr 1990; 117:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/34\">",
"      Hoorn EJ, Carlotti AP, Costa LA, et al. Preventing a drop in effective plasma osmolality to minimize the likelihood of cerebral edema during treatment of children with diabetic ketoacidosis. J Pediatr 2007; 150:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/35\">",
"      Durward A, Ferguson LP, Taylor D, et al. The temporal relationship between glucose-corrected serum sodium and neurological status in severe diabetic ketoacidosis. Arch Dis Child 2011; 96:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/36\">",
"      Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999; 106:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/37\">",
"      Adrogu&eacute; HJ, Wilson H, Boyd AE 3rd, et al. Plasma acid-base patterns in diabetic ketoacidosis. N Engl J Med 1982; 307:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/38\">",
"      Adrogu&eacute; HJ, Eknoyan G, Suki WK. Diabetic ketoacidosis: role of the kidney in the acid-base homeostasis re-evaluated. Kidney Int 1984; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/39\">",
"      Oh MS, Carroll HJ, Uribarri J. Mechanism of normochloremic and hyperchloremic acidosis in diabetic ketoacidosis. Nephron 1990; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/40\">",
"      Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/41\">",
"      Hale PJ, Crase J, Nattrass M. Metabolic effects of bicarbonate in the treatment of diabetic ketoacidosis. Br Med J (Clin Res Ed) 1984; 289:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/42\">",
"      Okuda Y, Adrogue HJ, Field JB, et al. Counterproductive effects of sodium bicarbonate in diabetic ketoacidosis. J Clin Endocrinol Metab 1996; 81:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/43\">",
"      Alberti KG, Emerson PM, Darley JH, Hockaday TD. 2,3-Diphosphoglycerate and tissue oxygenation in uncontrolled diabetes mellitus. Lancet 1972; 2:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/44\">",
"      Gibby OM, Veale KE, Hayes TM, et al. Oxygen availability from the blood and the effect of phosphate replacement on erythrocyte 2,3-diphosphoglycerate and haemoglobin-oxygen affinity in diabetic ketoacidosis. Diabetologia 1978; 15:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/45\">",
"      Fisher JN, Kitabchi AE. A randomized study of phosphate therapy in the treatment of diabetic ketoacidosis. J Clin Endocrinol Metab 1983; 57:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/46\">",
"      Wilson HK, Keuer SP, Lea AS, et al. Phosphate therapy in diabetic ketoacidosis. Arch Intern Med 1982; 142:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/47\">",
"      Zipf WB, Bacon GE, Spencer ML, et al. Hypocalcemia, hypomagnesemia, and transient hypoparathyroidism during therapy with potassium phosphate in diabetic ketoacidosis. Diabetes Care 1979; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/48\">",
"      Lawrence SE, Cummings EA, Gaboury I, Daneman D. Population-based study of incidence and risk factors for cerebral edema in pediatric diabetic ketoacidosis. J Pediatr 2005; 146:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/49\">",
"      Edge JA, Hawkins MM, Winter DL, Dunger DB. The risk and outcome of cerebral oedema developing during diabetic ketoacidosis. Arch Dis Child 2001; 85:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/50\">",
"      Muir AB, Quisling RG, Yang MC, Rosenbloom AL. Cerebral edema in childhood diabetic ketoacidosis: natural history, radiographic findings, and early identification. Diabetes Care 2004; 27:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/51\">",
"      Ghetti S, Lee JK, Sims CE, et al. Diabetic ketoacidosis and memory dysfunction in children with type 1 diabetes. J Pediatr 2010; 156:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/52\">",
"      Wootton-Gorges SL, Buonocore MH, Caltagirone RA, et al. Progressive decrease in N-acetylaspartate/Creatine ratio in a teenager with type 1 diabetes and repeated episodes of ketoacidosis without clinically apparent cerebral edema: Evidence for permanent brain injury. AJNR Am J Neuroradiol 2010; 31:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/53\">",
"      Worly JM, Fortenberry JD, Hansen I, et al. Deep venous thrombosis in children with diabetic ketoacidosis and femoral central venous catheters. Pediatrics 2004; 113:e57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/54\">",
"      Gutierrez JA, Bagatell R, Samson MP, et al. Femoral central venous catheter-associated deep venous thrombosis in children with diabetic ketoacidosis. Crit Care Med 2003; 31:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/55\">",
"      Carl GF, Hoffman WH, Passmore GG, et al. Diabetic ketoacidosis promotes a prothrombotic state. Endocr Res 2003; 29:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/56\">",
"      Haddad NG, Croffie JM, Eugster EA. Pancreatic enzyme elevations in children with diabetic ketoacidosis. J Pediatr 2004; 145:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/57\">",
"      Vanelli M, Chiari G, Ghizzoni L, et al. Effectiveness of a prevention program for diabetic ketoacidosis in children. An 8-year study in schools and private practices. Diabetes Care 1999; 22:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/58\">",
"      Drozda DJ, Dawson VA, Long DJ, et al. Assessment of the effect of a comprehensive diabetes management program on hospital admission rates of children with diabetes mellitus. Diabetes Educ 1990; 16:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/28/7626/abstract/59\">",
"      Beck JK, Logan KJ, Hamm RM, et al. Reimbursement for pediatric diabetes intensive case management: a model for chronic diseases? Pediatrics 2004; 113:e47.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5808 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7626=[""].join("\n");
var outline_f7_28_7626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assessment of severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Moderate and severe DKA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fluid and electrolyte deficits and repletion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30197583\">",
"      - Fluid repletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30197649\">",
"      Initial volume expansion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30197713\">",
"      Subsequent fluid administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Serum sodium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Serum potassium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Discontinuing the insulin infusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Borderline DKA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPLICATIONS AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6903862\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Aspiration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cardiac arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pancreatic enzyme elevations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5808|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/17/16671\" title=\"figure 1\">",
"      DKA nomogram sodium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/4/23629\" title=\"table 1\">",
"      DKA rapid overview child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 2\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/3/3132\" title=\"table 3\">",
"      DKA neuro state children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/13/11483\" title=\"table 4\">",
"      Assessment of severity of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16983?source=related_link\">",
"      Cerebral edema in children with diabetic ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41480?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44295?source=related_link\">",
"      Epidemiology and pathogenesis of diabetic ketoacidosis and hyperosmolar hyperglycemic state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=related_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25891?source=related_link\">",
"      Potassium balance in acid-base disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/1/21526?source=related_link\">",
"      The &Delta;anion gap/&Delta;HCO3 ratio in patients with a high anion gap metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_28_7627="GI priming in preterm infants";
var content_f7_28_7627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F68719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F68719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages of gastrointestinal priming (trophic feeding) in preterm infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Shortens time to regain birth weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improves feeding tolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces duration of parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enhances enzyme maturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces intestinal permeability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improves gastrointestinal motility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Matures hormone responses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Improves mineral absorption and mineralization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces duration of phototherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lowers incidence of cholestasis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7627=[""].join("\n");
var outline_f7_28_7627=null;
var title_f7_28_7628="PD cath sinus appearance";
var content_f7_28_7628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading of pertioneal catheter sinus tract based upon exit site appearance",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Good",
"       </td>",
"       <td class=\"subtitle1\">",
"        Equivocal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute infection &lt;4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic infection &gt;4 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cuff infection without exit infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epithelium",
"       </td>",
"       <td>",
"        Strong, mature. Covers visible sinus",
"       </td>",
"       <td>",
"        Strong, mature at rim. Fragile or mucosal deeper",
"       </td>",
"       <td>",
"        Absent or covers part of sinus",
"       </td>",
"       <td>",
"        Absent or covers only part of sinus",
"       </td>",
"       <td>",
"        Absent or covers only part of sinus",
"       </td>",
"       <td>",
"        Covers most or all of sinus. May be macerated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulation tissue",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Plain beyond epithelium",
"       </td>",
"       <td>",
"        Slightly exuberant",
"       </td>",
"       <td>",
"        Slightly exuberant or 'proud flesh'",
"       </td>",
"       <td>",
"        'Proud flesh' or slightly exuberant",
"       </td>",
"       <td>",
"        None or exuberant deep in sinus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Drainage",
"       </td>",
"       <td>",
"        None or barely visible",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        None or barely visible",
"       </td>",
"       <td>",
"        Purulent or bloody.",
"       </td>",
"       <td>",
"        Purulent or bloody",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent or bloody",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Purulent, bloody, gluey. May be seen only after pressure on cuff. Clot or dreed blood in sinus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clear or thick",
"       </td>",
"       <td>",
"        Clear or thick",
"       </td>",
"       <td>",
"        Sometimes clear",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Twardowski, ZJ, Prowant, BF. Nephrol Dial Transplant 1997; 12:1284. Copyright &copy; 1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7628=[""].join("\n");
var outline_f7_28_7628=null;
var title_f7_28_7629="Schematic depiction of solute mvmt in dial";
var content_f7_28_7629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F51887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F51887&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Schematic depiction of solute movement in dialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 177px; background-image: url(data:image/gif;base64,R0lGODlh/wGxANUAAP////8AAICAgH9/f/9/fwAAAEBAQMDAwNDQ0DAwMKCgoODg4PDw8CAgIGBgYFBQUD8/P5CQkH8AAP+AgL+/v7CwsHBwcN/f3y8vL8/PzxAQEO/v7x8fH09PT19fX5+fn29vb6+vr4+Pjw8PD38/P78/P7+AgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD/AbEAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz7QHAtPU1dbX2Nna29zd3t/g4eIH0OWDAhAD6uvs7e7v8PHy8/T19vf49xAC5v1/AgP8DRnAT6BBPAAPEjzIsE5CgwsbSoTzUGDEiRjXVPR3MaNHMxv7dfxIMkxIcyNLquRyslzKlTCvtIT2MqZNKTOf1bzJs0lO/2c7ewpF8rNZ0KFIhxRldjRplAMMqixYcMQCAiIHsiJB8MCAAgWllsq5QKHsEBAZoHz44KfpHgRRhUzVhaBAwSIGyC35eiQvEQF2kTSAO82QhgcRrmoRG2dAOhAcNgCAQAGKurZ35RxO7CSChSEJFKsp0MiBgAZKFwg40MA0AAYODBRUgCBCVnIKDMgW4pcIaQALFAgwEAHAAbvC+S2IDRbA7KgKqNopQL1A6+gyA/a5PLkyZQAUOnSoDOCCBwhsy59Ph7lOdesOsCdZgBo4ati7ASio8OCB9NwOUKWVc0IM94BowCkgDQBcGVCBccgFJwR2tNl2QAWx6ZWHBgyEJv9EAbIhkIBtACRAjgX8GNDAaoVBBcADYPU2xG+sQdXAVAUcgEBhDUAFIwB5MaABWL/5JM6R1rz3XgIWPDgFY3AM4AEFH0AgBGUXcHBBlhcAwAEFG3TAFgaVeaAdH00hqeY0SlbHpJNGeOhZiSemaAEDETig3wMMsOZcQaRF8ACDcBp3mAALJLAAA3ktkCMCBxjAGzkqsmjAAgjUhwd/AMwJQJF+ZTpNbEDqVZhqlZZaBI2SqvrbNAi0esCg0wh3YKtGrnlkm9SFSAWUbzimDgYhdCeCdgOIkIGV4HWQAQZCcIdmZkTpuiuvvh4xZ2iiCkCqX5G+qJcBOwKqXwK0FRH/bqeyDccPq5Oq+ueHejjQgAEJ1AcqOQeYmNVVvU1D34OFyUivca369epqsko6K59eUTvHkk1iAawb3IVgJWXcqUMBsx9/HO2Ze7iFBsWFIkEffcb5q6Oq4faWV2GfCnGABSti1aq3t1EFr6oBm7thXB6C+qCQigFs6moJCOGawTUjHO/CAHDoXHEl6hmBiXhcJ10WF7fBnQgedPfslWmNIFmyG6gNAAgk62HyGV5DkUAC/CAthNJSz8kAanM6ymBUFeAqtXENxHVVAVGJ+BrXQR98B6dCzFlkBQlIKiK+KS4NgAOZP9A5EQaAeLjCBfKDeQIOxPWj4JeEzcYAHECA/0EHkn03AAYYaBcC7x5I9sHtHcSdx9x6KFCAdJvjDbOksN199L0WkIY5vgiuey6+BDP5YgIPQO551E6dITsxyJcf0/nDpK/+SuwL4/77JcUfzPz0f2Q/HGY1gn/+GdlfsIyHiP8BcCICxBgBD2HAAzYkgWJboCEa6MCDQHB2EiwEBSsokAuuQVqL2CAH++FBNYBQESIcYTlKmIYTJiKFKnwGC9HgwgJKLIbwy+B2dDgIGOKQGTM8Qw0ZeMMfkiSIZhjiBItoRI8gsQxK1CATm4iRJ5IhioTwIRWPYcUxYLGHU9ziA3lYMjIGQotiJEYXxfBFQaAxjcJYYxjaeMYwwv+xg2Y8Xh7/8MY7/kKOYKAjIProx14A8guC5KMdC7nCPd4hke1hJAIdaQdIbmeRknTGIb1gyWllUiImKAEBRknKUprylKhMpSpXyUpTkoAErYylLGdJy1SWwASfbMgEAsDLXvryl8AMpjCHScxiAlMCEjCmMpfJzGYOcwK5ZMgunUnNajoTmdbMpjabCc1oGmSa2wznNrEpznKas5ve9Ac4zcnOZZKznfCkJjrTaY51xvOev3wnPvf5THqqk58ADYA+A0rQefrzGfYkaDsHqlB+GvSgzUhoQ8vJ0Ine86EQXYZELTrOZHLUoUk4wNdEGgXDZVQVG/2oNSuq0nMmwXT/EMLkjE7aipS29JoevSk8MfohB5DDAa5xjgFaZxwMkatwevpUbj6jn9pkpStEvVCGhFC4A9FUEjbVqTtzqlWXIqEAXFmA6PiBIgAUTqiYGtKLiEQOxABpRTqiSp7Qmimz8ok+cbmqI7La1WKytK/W5GnNdCMNfmiAGqShGdXg1Rs8hU9Sin2RaU6jIb0ygq+AFeZfM+tMwZImXIXJ0W3mFbXQ2kxSvRlRnyBrLuLcJq+WXQRmOZtPrtI2sC/9S4qwdpXIzus3FihObxinH9bSSwCDes3XYquI2d6Wl5t9rjE9q9vXhA98pF0svojaGwXci1S+tUDmFMXcy0p3q+fF/215j+Hc50Y3vcIU7Hp90d7bvhe+wJTvfHlRX9reF7++1O9+ddFfzv4XwLwU8IBxUeDMHhjBCl6wLRoM2AcDOMISpgWF+2ph/GI4w7LYcFc7DN8PgxgWoaylildcy1ey+MUwnuUtT/xHStahkyWTKY1fscku4FhuOt5xK3rMhR8fL8hCXgWRt2BkPBAyyZlYshaa/EgkQxkVUs4ClStp5SubIstY2PKNu+xlUoD5CmKmw5PLTIkzWyHNc1gzmyXh5irAWQ5ynjMk6kyFOzeGzHr+BJ+n4OcoATrQnRi0FAodrEMjehOKjgKjMeboR0fZxmrGNJAtDYtIW0bTR+Y0j/9B/QYOvGcEjMizqBHh6SZ44D0dSHWlV91mUrvhA+8RgaxpzYpWM+EC70lLCGfN60j4mgkYoA4H/EfsYj/i2EsAAXXKtmtnY9nWbggBddIzbGtf+xDU6VK1vR0WbLvBdo5QNbn/YW6xgSDdzV53IqC9hAwUi9nyNnO7eaHufO+B3prot7/zAPBMCHzgdyg4Jg6OcIfsexcMb/gcFH6JiEs8DhS3hMWV0bMhMABBQ+DLGxok8lEMmiz9EwJ5ipCBdz9i41nouBA+foSSc4HmRyicBawCB7sg1wCNY2oRaAYFqE2hN4NhANFFMWhhgQAD6WFWEUQWBapvGtzT6ErQj7D/dCcYvQgIEDoR8MqoyrKhSLlJkHGgGhVYNWcBxTHQVXKzG/q4Bj8SA5CATGUf0xxHAMkBDnMKNCHoLHcKwbHXvx8eZu1sgEwACIh5IOAs8EBgA2cawAYy0AH2TL7ytBtAZTRWeTWTOfGaOnvIJSWhWQ217QJAwNvjbgCr0l05rclbbKjVeqOS4zQM41d/yCGhThE+DEUCwGDChQC56mkaQmp7cAeFgAe5CEYdIhHXyhpyPvkpstkX6aN45KMYQUWtyY9CBcT7nsXf+EwfiDVpLpCWDCxbZJCnALRGkIEN6Jr+AGB/ADA8FHABIYA7WSIZcYZk65cA7ecGybd8muN8/38Sfc4xfYRiHFGBfSNCDtuXGaB1KXWlACayAI1yIytTMxWgAQugPV+QfHkRLo6VOfMSH8oXHOiiGKiSM6GyIt5iOA8wLuVyMMOVOrFiM7QCeMh1hFCwI6XDK9ZyJIfHBE13JiLzGx9wHqQhMlkIAB7AFhwAAmAiBFkIAVvILB1gJrSzcn/mBE7IKz4XheBweDCYFdAjKDRYGDZ4IySYLsAxHDxIDt1CKkMAWuayLnkRAQUhAMJ1AKYRAYooBhG4WiUSAZRYGJlCOTezIgMzL+DiMggiM4VFhHqxMOsSLg/DKMKhfuwHhXI4h1FQhUPwAe9GGiDgAV1yhkLAf6gGAP/+1wFqc4u5aHlXIgJlMYYL6AQNCIevCIu+QQSJEy6qZYgM0gCaiDOIYo2eyC+gqDPZdTqjOC+MCHQP4FOSOAQO8BnhQlxpRzMqIoiEkxdN8zkpcjQakDRE4DeA8xmw4yAHUxhWw4hCwDqdwjWIpwD28oAEx3hoph32N4wQUCzARoyRxwHaQR5kEpHlsYXQEnmx5ovihmdBhnoKqXpOo46Swo7G9VbwaFby6DT1+Br3uDfeGFmIqCPzSC4MMiLfMwYgwjmnpR/ftZIkSFXjdRWgU3uqQ4PNkxnRkwDTYwDVY5QpmTpmdTdEtVbAkX5UUBsPoAHup2a1czvCRhr2BwH/0kaRwKaAHcA773aWaTkZ6PE2GGA7IdmGXSkoYAmBuuE8UuNdQ0WU83g9HpKUonOVmjNeILiSn5Uwv3c3d8GCxXUHNohHidCF3bYJlbkKLGMQGXcEWjJumNCZDfeZlABzF9cGpjkJqJmaGsGQuNCarpkGqykJsjmb5gObt3CbuFkGtRkJvNmbY/CbkBCcwmkSumkLxnmcX0CcLxdvzIkQyVkLyxmdLDGdtFCd1rkY2DkL2rmdFtOdsvCd4GkF6JAP6Jme6rme7Nme87AP5QkJhdWM9Fmf9nmf12B28bmf/Nmf/vmfABqgAjqgBFqgBnqgCJqgCrqgDNqgDvqgEBqhFBI6oRRaoRZ6oRiaoRq6oRyaCUEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the movement of solute from blood to dialysate across the dialysis membrane. Blood and dialysate move in opposite directions (ie, flow in a countercurrent fashion) to maximize the clearance of solute.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7629=[""].join("\n");
var outline_f7_28_7629=null;
var title_f7_28_7630="Gaucher treatment goals A";
var content_f7_28_7630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75418%7EPEDS%2F54387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75418%7EPEDS%2F54387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=13\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic goals in the treatment of Gaucher disease - part 1",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Goals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Hgb &lt;12 g/dL in males &gt;12 years",
"        </p>",
"        <p>",
"         Hgb &lt;11 g/dL in females &gt;12 years",
"        </p>",
"        <p>",
"         Hgb &lt;10.5 g/dL in children 2 to 12 years",
"        </p>",
"        <p>",
"         Hgb &lt;9.5 g/dL in children 6 mos to 2 years",
"        </p>",
"        <p>",
"         Hgb &lt;10.1 g/dL in children &lt; 6 mos",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Increase Hgb within 12 to 24 months:",
"        </p>",
"        <p>",
"         to &ge;11",
"g/dL for children and females &gt;12 years",
"        </p>",
"        <p>",
"         to &ge;12",
"g/dL for males &gt;12 years",
"        </p>",
"        <p>",
"         Eliminate dependency on blood",
"transfusions",
"        </p>",
"        <p>",
"         Reduce fatigue, dyspnea, angina",
"        </p>",
"        <p>",
"         Maintain improved Hgb values",
"achieved after the first 12 to 24 months of therapy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Thrombocytopenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Moderate: platelet count between 60,000 and",
"120,000/microL",
"        </p>",
"        <p>",
"         Severe: platelet count &lt;60,000",
"        </p>",
"        <p>",
"         Risk for surgical or obstetrical bleeding: platelet",
"count &lt;30,000/microL",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         All",
"patients:",
"        </p>",
"        <p>",
"         Increase platelet count in the first",
"12 months of treatment to prevent surgical, obstetrical, and",
"spontaneous bleeding",
"        </p>",
"        <p>",
"         Patients",
"with splenectomy:",
"        </p>",
"        <p>",
"         Normalization of platelet count by",
"one year of treatment",
"        </p>",
"        <p>",
"         Patients with intact spleen:",
"        </p>",
"        <p>",
"         Moderate thrombocytopenia: increase",
"the platelet count by 1.5- 2.0-fold in first year; approach low normal",
"level by second year",
"        </p>",
"        <p>",
"         Severe thrombocytopenia:",
"        </p>",
"        <p>",
"         Increase the platelet count by 1.5 fold during the",
"first year and",
"continue to increase slightly during the second through fifth years;",
"double platelet count by second year; complete normalization is not",
"expected",
"        </p>",
"        <p>",
"         Avoid splenectomy",
"        </p>",
"        <p>",
"         Maintain stable platelet counts to",
"eliminate risks of bleeding after a maximal response has been achieved.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Hepatomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Moderate: Liver mass &gt;1.25 times the normal 2.5",
"percent of total body weight in kg (assessed by quantitative imaging,",
"preferably MRI)",
"        </p>",
"        <p>",
"         Severe: Liver mass &gt;2.5 times",
"normal volume",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        <p>",
"         Reduce and maintain the liver volume",
"to 1.0 to 1.5 times normal volume",
"        </p>",
"        <p>",
"         Reduce liver volume by 20 to 30",
"percent within the first two years of treatment and by 30 to 40 percent",
"by the third to fifth year",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table is continued.",
"    <div class=\"footnotes\">",
"     Hbg: hemoglobin; MRI: magnetic resonance imaging.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4, Baldellou A, Andria G, Campbell PE, et al. Paediatric non- neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic goals in the treatment of Gaucher disease - part 2",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Manifestation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Goals",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Splenomegaly",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Splenic mass &gt; the normal 0.2 percent of total body weight in kg.",
"       </p>",
"       <p>",
"        Moderate: &gt;5 and &le;15 times normal volume",
"       </p>",
"       <p>",
"        Severe: &gt;15 times normal volume (assessed by quantitative imaging, preferably MRI)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Reduce and maintain spleen volume to &le;2 to times normal",
"       </p>",
"       <p>",
"        Reduce the spleen volume by 30 to 50 percent within the first year and to 50 to 60 percent by the second to fifth years",
"       </p>",
"       <p>",
"        Alleviate symptoms due to splenomegaly (abdominal distension, early satiety, new splenic infarction)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Skeletal pathology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       <p>",
"        Focal disease: Lytic and sclerotic lesions associated with infarction, thrombosis, and inflammatory processes that can progress to osteonecrosis",
"       </p>",
"       <p>",
"        Local disease: remodeling defects of the long bones and long bone deformities",
"       </p>",
"       <p>",
"        Generalized osteopenia and osteoporosis",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        All patients:",
"       </p>",
"       <p>",
"        Retain skeletal function by preventing the onset of new skeletal complications",
"       </p>",
"       <p>",
"        Lessen or eliminate bone pain within first or second year",
"       </p>",
"       <p>",
"        Prevent bone crises or decrease frequency",
"       </p>",
"       <p>",
"        Prevent osteonecrosis and subchondral joint collapse",
"       </p>",
"       <p>",
"        Improve bone mineral density",
"       </p>",
"       <p>",
"        In children:",
"       </p>",
"       <p>",
"        Attain normal or ideal peak skeletal mass",
"       </p>",
"       <p>",
"        Increase cortical and trabecular BMD by second year",
"       </p>",
"       <p>",
"        In adults:",
"       </p>",
"       <p>",
"        Increase trabecular BMD by 3 to 5 years",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Growth",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Normalize growth such that child achieves a normal height according to population and family history by the third year of treatment",
"       </p>",
"       <p>",
"        Achieve normal onset of puberty",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Pulmonary involvement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Reverse hepatopulmonary syndrome and dependency on oxygen",
"       </p>",
"       <p>",
"        Ameliorate pulmonary hypertension (ERT plus other therapies)",
"       </p>",
"       <p>",
"        Improve functional status and quality of life",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"       Functional health and well-being",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <p>",
"        Improve or restore physical function for carrying out normal daily activities and fulfilling functional roles",
"       </p>",
"       <p>",
"        Improve scores from baseline of validated quality-of-life-instruments within the second or third year, depending upon disease burden",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4.",
"      <br>",
"       Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7630=[""].join("\n");
var outline_f7_28_7630=null;
var title_f7_28_7631="Sacroiliac tenderness I";
var content_f7_28_7631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Testing for sacroiliac tenderness",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient can be examined for sacroiliac joint tenderness due to active sacroiliitis by applying direct pressure over each sacroiliac joint.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_28_7631=[""].join("\n");
var outline_f7_28_7631=null;
